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ABSTRACT
Patrick Dib, M.S., Department of Biological Sciences, Wright State University, 2008.
The effects of a nutritional supplement, Mass FX, on muscular strength, body
composition, and blood chemistries in resistance trained adult males
The purpose of this study was to determine the effects of a nutritional supplement, Mass
FX, on muscular strength, body composition, and blood chemistries in resistance-trained
adult males. Eight subjects, mean age 25 +/- 3.02 years, were randomly assigned to two
groups (n=4). Each group was given either Mass FX or a Placebo in a double-blind
manner to be taken orally for six weeks (4caps/day regardless of bodyweight). For the
duration of the study, both groups were following the same training program and a diet
customized to each subject’s bodyweight in conjunction to the supplementation. Data
were analyzed using Analysis of Covariance (ANCOVA) with a Bonferroni correction
resulting in a family-wise level of significance of α = 0.05, to avoid inflation of the Type
I error. To confirm results, an independent samples t-test using a Bonferroni correction
with a family-wise level of significance of α=0.05 was performed. Using ANCOVA, the
groups were significantly different for the Bench Press outcome; whereas using the
independent samples t-test, the two groups were significantly different for Bench Press
and Free Testosterone. The results of this study indicate that supplementation with Mass
FX induced better improvements than Placebo in muscular strength as measured by the
bench press (p<0.05). Other measures in muscular strength, body composition, and free
testosterone showed improvements, but were not statistically significant (p>0.05). No
adverse effects on selected clinical health markers: complete blood count with
differential, hepatic (AST, ALP, ALT), lipids (TC, TGs, LDL, VLDL), and renal
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(creatinine, BUN) were observed from Mass FX supplementation (Group significance
p>0.05). Mean difference (Post-Pre) in total and free testosterone concentrations
exhibited apparent increases in the Mass FX group, in contrast to Placebo in which
reductions in both mean difference total and free testosterone concentrations were
observed. Lack of significance in the remaining variables of interest could be attributed to
low power because of the small sample size used in this study. Thus, due to limitations in
terms of sample representation and size, this study should be considered a pilot study.
Future studies need to investigate these parameters using larger sample sizes.
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CHAPTER I
INTRODUCTION
The desire to enhance performance and physical appearance has been a mission
sought since the ancient times. An approach used to achieve these aforementioned goals
includes the use of dietary supplements. Paintings of Shen-Nung, a Chinese emperor,
dating back to 2737 B.C. show him with leaves of Ma Huang. Ma Huang, commonly
known as ephedra, is a plant that has stimulant properties. Ephedra was a very popular
supplement used by individuals seeking weight loss and improved performance until its
ban in 2004 (De Rose, 2008). Athletes during 500-400 B.C used to consume animal
organs believing they would become more courageous and stronger (Applegate &
Grivetti, 1997). Greek wrestlers ingested sesame seeds with meat in efforts to build more
muscle (Carpenter, 2007). Andean Indians consumed coca leaves to prevent fatigue
(Carpenter, 2007). In addition, there has been mention in Norwegian literature that
Viking warriors used hallucinogenic mushrooms to prepare for battle (Prokop, 1970).
Today, the ways have changed, yet the purpose has stayed the same – physique and
performance enhancement.
Ancient practices lacked scientific background. However, currently with advances
in science, medicine, and food technology, new forms of ergogenic aids started to
emerge. During the 1940’s and 1950’s, testosterone and its analogues made their way
through sports after the successful synthesis of testosterone in the 1930’s (Carpenter,
2007). During this period, the Soviet athletes were dominating in world competitions. In
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efforts to beat the Soviets in sporting events, the United States sought to research and
develop potent anabolic steroids. One of the major steroid discoveries was the
introduction of methandrostenalone (Dianabol) by an American physician Dr. John
Zeigler (McDuff & Barron, 2005). Since then, anabolic steroids have become a major
concern and problem in sports.
In addition to anabolic steroids, stimulant use in the form of amphetamines and
other sympathimimetic amines by athletes has been popular since the 1940’s (McDuff &
Barron, 2005). Their use ranged from weight loss (physique enhancement and making
weight) to improved energy levels (improved athletic performance). Another substance
used to enhance performance especially in endurance events is erythropoietin (Elliot,
2008). EPO, a peptide hormone, has been shown to increase red blood cell counts. This
translates into better oxygen saturation and supply to skeletal muscle tissue and in turn
improves performance (Elliot, 2008).
Despite the ergogenic benefits of these compounds, they pose a major health,
legal, and moral problem (Laure & Biosinger, 2005). It is noteworthy to mention that not
only are elite professional athletes abusing these controlled substances, but both male and
female teens and pre-adolescents are using them, too (Carpenter, 2007). With this in
mind, there is a clear concern to offer solutions to this problem. Thus, there is a need for
the scientific community to provide research on legal alternative products such as dietary
supplements that would improve athletic performance with no adverse effects on health.
In turn, this will help in reducing the alarming prevalence in which banned substances are
being abused.

2

Testosterone
Testosterone, a 19-carbon steroid, is the primary male sex hormone (Chang, 2002,
p.1-2,353; Kadi, 2008). It has both anabolic and androgenic properties; thus, it regulates
the male sexual characteristics and influences muscle hypertrophy (Kadi, 2008). The
leydig cells in testes are the main site of production in males. Another indirect site of
production is the adrenal glands. The adrenal glands secrete the testosterone precursors
dehydrorpiandrosterone and androstenedione (Chang, 2002, p.1-2,353). Testosterone has
many physiological benefits such as sexual development, overall health, immune
function, muscle mass maintenance, and protection from osteoporosis (Chang, 2002, p.12,353). Increasing testosterone levels aids in improving exercise performance, recovery,
and appearance due to its anabolic activity on skeletal muscle (Kadi, 2008). Having said
this, there are multiple mechanisms in which testosterone triggers skeletal muscle
hypertrophy (See Figure 1). Testosterone may increase in the number of PCNA+
(proliferating cell nuclear antigenpositive) satellite cells in human skeletal muscle (Kadi,
2008). In turn, these satellite cells mediate myotrophic action in response to testosterone
(Kadi, 2008). Other mechanisms initiating muscle hypertrophy via testosterone are
myonuclear accretion and enhancement of myonuclei numbers (Kadi, 2008). Not only
that, but the activation of satellite cells via testosterone can lead to proliferation and
differentiation into new myotubes (Kadi, 2008). Finally, testosterone has the capability to
induce expression of myogenic markers in mesenchymal pluripotent cells, which favors
them to differentiate into myocytes (Kadi, 2008)

3

Figure 1: Testosterone mode of action on skeletal muscle (Kadi, 2008)

A Brief Review of Benefits Associated With Dietary Supplements
There have been numerous studies reporting benefits to dietary supplement use.
An example of such would be creatine. Creatine’s ergogenic benefits are due to enhanced
energy production in the muscle cells, thus it increases muscular power output (Kleiner,
2007, p. 160-161). Not only does creatine enhance exercise performance, it also
possesses therapeutic properties. In addition, Creatine improves skeletal muscle
responses to exercise in chronic heart failure patients (Andrews et al., 1998). Another
ergogenic aid with medicinal implications is Coenzyme Q10 (Ubiquinone). Coenzyme
Q10 has been recently shown to reduce exercise-induced muscular injury in athletes. In

4

addition, it increases aerobic exercise performance and has been shown to be a beneficial
supplement to treat heart disease (Kleiner, 2007, p.124-125).
Other notable dietary supplements that have been studied extensively with
positive results include cinnamon extract, beta-alanine, and beta-hydroxy-betamethylbutyrate. Cinnamon extracts positively alter body composition due to their insulin
modulation properties (Integrity, 2007). Also, cinnamon extracts moderately reduce
glucose concentrations in diabetics (Mang et al., 2006).
Beta-Alanine is an amino acid that is used by the body to synthesize carnosine, a
dipeptide found in skeletal muscles. Enhanced carnosine levels in skeletal muscle tissue
improve buffering H+ ions in muscle tissue (Kendrick et al., 2008; Harris et al., 2006).
Therefore, it is suggested that carnosine may improve exercise performance (Parkhouse
& McKenzie, 1984; Hill et al., 2007). Not only that, but carnosine can be used to treat
various ailments due its antioxidant effects (Zeiba, 2007). Finally, research performed on
Beta-hydroxy-beta-methylbutyrate, a metabolite of the amino acid leucine, suggests that
it prevents muscle breakdown and helps in increasing muscle strength (Kleiner, 2007,
p.169). Thus, beta-hydroxy-beta-methylbutyrate is not used only for ergogenic purposes,
but also for therapeutic cases like muscle wasting diseases (Rathmacher et al., 2004).
Testosterone Boosters
A particular class of ergogenic aids referred to as testosterone enhancing dietary
supplements are being marketed and sold nowadays. Testosterone is the major circulating
sex steroid hormone in males. It is responsible for the development of secondary sexual
characteristics including muscle growth via increased protein synthesis. Therefore,
increasing testosterone levels is suggested to increase muscular hypertrophy. The premise
5

of increasing testosterone levels and its subsequent muscle growth stimulating properties
has been illustrated in a study conducted by Bhasin et al. (2001). Bhasin et al. concluded
that increased testosterone levels from an exogenous source improved muscle strength
and mass in a dose dependent manner. Unfortunately, testosterone from exogenous
sources is a controlled substance. Thus, nutritional supplement companies aim at
producing products that aid the body in naturally producing more testosterone. These
products are referred to as testosterone boosting supplements and are marketed as
ergogenic aids. An example suggesting the efficacy of this class of ergogenic aids is
discussed in a study entitled “Eight Weeks of Aromatase Inhibition Using the Nutritional
Supplement Novedex XT: Effects in Young, Eugonadal Men” (Willoughby et al., 2007). This

study has shown that Novedex XT supplementation has increased serum testosterone
levels without any changes in clinical health markers, and reduced body fat (Willoughby
et al., 2007). This suggests that it is safe and an effective ergogenic product.
Hormonal Responses to Resistance Training
Resistance training is associated with significant elevations in anabolic hormones
such as insulin-like growth factor-1 (IGF-1), growth hormone, and testosterone (Kraemer
& Ratames, 2005). The elevations in these anabolic hormones are suggested to be
responsible for the adaptive mechanisms in response to resistance training (Kraemer
& Ratames, 2005). In particular, the increases in testosterone are in response to a single
bout of resistance training. However, it seems that these elevations are transient and do
not affect basal testosterone concentrations (Kraemer & Ratames, 2005).Thus, one of the
purposes of this study is to investigate whether Mass FX increases basal testosterone
concentration.
6

Mass FX™
This study will focus on Mass FX, a testosterone enhancing product that is
manufactured by Anabolic Xtreme (Tempe, Arizona). The compounds found in this
formulation pertain to two groups. According to the manufacturer, the first group of
compounds are suggested to have anabolic activity and are composed of (3b, 5a, 6a,
25R)-spirostan-3,6-diol (Chlorogenin), and (-)-3,4-divanillyltetrahydrofuran (DVTHF).
Chlorogenin and DVTHF are plant extracts from the Chlorogalum pomeridianum
(O’Neil et al., 2006) and Urtica dioica (Schöttner et al., 1997), respectively. The second
group of compounds is included in the formulation to enhance the bioavailiabilty and
absorption of the aforementioned anabolic compounds. These compounds are 6',7'Dihydroxybergamottin (6,7DHB) and Bioperine®. The compound 6,7DHB is extracted
from grapefruit juice (Row et al., 2006); Bioperine® is extracted from black pepper
(piper nigrum) (Sabinsa, 2005). All ingredients in this product are compliant with the
Dietary Supplement Health and Education Act (DSHEA). They are not included on the
current National Collegiate Athletic Association banned or controlled substances list.
Thus, they are legal to obtain and consume under the DSHEA.
Statement of Purpose
The purpose of this study was to determine if Mass FX enhances performance and
whether these improvements can be attributed to increase in testosterone concentration.
Specifically, this study was conducted to:
•

Determine the efficacy of Mass FX™ on increasing total and free testosterone.

•

Determine the efficacy of Mass FX™ on improving body composition by
increasing lean mass and decreasing fat mass.
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•

Determine the efficacy of Mass FX™ on increasing muscular strength.

•

Determine the effects of Mass FX™ on the selected clinical health markers (See
Appendix F).

Hypotheses
In order to ascertain the effects of Mass FXTM on strength, testosterone, clinical
health markers, and body composition, the following null hypotheses were identified.
Ho1: Supplementation with Mass FX™ will not cause an improvement in body
composition.
Ho2: Supplementation with Mass FX™ will not cause an increase in total testosterone.
Ho3: Supplementation with Mass FX™ will not cause an increase in free testosterone.
Ho4: Supplementation with Mass FX™ will not cause an increase in muscular strength.
Ho5: Supplementation with Mass FX™ will not cause a change in clinical health markers
(See Appendix F).
Operational Definitions
The following are defined for this study.
SHBG (Sex Hormone Binding Globulin): a glycoprotein that binds specifically to sex
hormones such as testosterone. SHBG binds to testosterone with high affinity and
subsequently attenuate the metabolic clearance of testosterone (Parker, 1993, p.1).
Testosterone: is a steroid with anabolic and androgenic properties (Kadi, 2008).
Nutritional ergogenic aids: refers to nutritional supplements that can enhance athletic
performance (Antonio & Stout, 2001 p.15).
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Dietary supplement: Under the DSHEA (Dietary Supplement Health and Education Act)
of 1994, a dietary supplement is considered a product taken orally that contains a
"dietary ingredient" intended to supplement the diet. According to the U. S. Food and
Drug Administration a dietary ingredient is:
“The "dietary ingredients" in these products may include: vitamins, minerals,
herbs or other botanicals, amino acids, and substances such as enzymes, organ
tissues, glandulars, and metabolites. Dietary supplements can also be extracts or
concentrates, and may be found in many forms such as tablets, capsules, softgels,
gelcaps, liquids, or powders. They can also be in other forms, such as a bar, but if
they are, information on their label must not represent the product as a
conventional food or a sole item of a meal or diet. Whatever their form may be,
DSHEA places dietary supplements in a special category under the general
umbrella of "foods," not drugs, and requires that every supplement be labeled a
dietary supplement”(U. S. Food and Drug Administration, 2001, para.1).
Androgens: male sex hormones responsible for producing male characteristics. Major
androgens include testosterone and its metabolite dihydrotestosterone. Androgens also
include the testosterone precursors: dehydroeoiandrosterone and androstenedione (Chang,
2002, p.1-2).
Anabolic: refers to the physiological change that leads to an increase in lean muscle mass
(Antonio & Stout, 2001, p.15).
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Assumptions
The following assumptions were considered for this study.
1. Participants attended the training sessions as determined by the principle
investigator.
2. Participants performed only the exercises assigned to the study protocol.
3. Participants followed dietary and supplement regimens throughout the study.
4. Participants informed the principle investigator or assistants of failure to
follow the accepted guidelines.
5. All participants had similar active lifestyles, body types, and activities of daily
life.
6. Participants refrained from alcohol, sexual activity, intense physical activity,
and exercise two days before pre and post trial testing.
Significance
The importance of this study was to determine the effects of Mass FX ™, a
dietary supplement, touted to increase testosterone in adult males. Mass FX ™ contains a
combination of ingredients that can be obtained from plant extracts: chlorogenin (a plant
saponin from the California soap plant), (-)-3,4-divanillyltetrahydrofuran (an extract of
the nettle root plant), bioperine (black pepper extract), and 6’,7’-dihydroxybergamottin
(grapefruit extract).
Previous studies performed on related plant extracts particularly saponins from
the tribulus terrestris plant showed that were no significant increases in testosterone
levels and exercise performance (Antonio et. al, 2000; Neychev & Mitev, 2005;
Rogerson et al., 2007). In addition, studies performed on (-)-3,4-divanillyltetrahydrofuran
10

do not address the changes in testosterone levels and exercise performance. Instead,
studies performed on (-)-3,4-divanillyltetrahydrofuran focus on the compound’s
capability to bind to sex hormone binding globulin (SHBG) (Schöttner et al., 1997;
Schöttner et al., 1997; Schöttner et al., 1998)
In this study, a new type of saponin, chlorogenin, was investigated with a
combination of other compounds. Thus, the significance of this study was that it
addresses the ergogenic effects of a combination of unique compounds that have yet to be
studied in terms of ergogenic potential. However, since the product is comprised of
multiple ingredients, it would not be possible to attribute any observed change to one
compound only. Thus, this study aims at determining the ergogenic effects and clinical
changes of Mass FX as a whole.
Summary
This chapter discussed the history and modern trends of using dietary
supplements. In addition, it discussed the importance of researching supplements to
obtain compelling scientific evidence in favor of these ergogenic aids. This would
educate the consumer on these products and will help in preventing athletes from using
illicit drugs and help them to chose and adhere to safe, moral, and healthy scientifically
backed dietary supplements. Finally, this research project would study the efficacy of
Mass FX™, a testosterone boosting supplement.
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CHAPTER II
REVIEW OF THE LITERATURE
This chapter will discuss the function of each ingredient of Mass FXTM. In
addition, the function of testosterone and its effect on skeletal muscle will be discussed.
Finally, this chapter will conclude with a summary.
Mass FX™ Ingredients
Touted Anabolic Compounds
1. (3b, 5a, 6a, 25R)-spirostan-3,6-diol (Chlorogenin)
Saponins are plant extracts with a sugar molecule bound to a steroid backbone.
They have been used in traditional medicine in treatment of various disorders notably
sexual impotence (Oshima & Gu, 2003). To validate this, in vivo studies have shown that
saponins elevated testosterone levels significantly (Oshima & Gu, 2003), thereby
suggesting a mechanism by which saponins induce their aphrodisiac effect. Not only do
Saponins have aphrodisiac properties, they are also used in reducing the incidences of
angina pectoris (Wang et al., 1990). Such is the case with saponins extracted from
Tribulus terrestris plant (Wang et al., 1990). Research performed on animal in vivo models

has demonstrated enhanced testosterone production as a result of Tribulus terrestris
administration (Gauthaman, 2002). However, studies conducted on adult human males
have shown that Tribulus terrestris does not exert any testosterone boosting or
performance enhancing effect (Antonio et. al, 2000; Neychev & Mitev, 2005; Rogerson
et al., 2007).
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Besides Tribulus terrestris, saponins are extracted from a variety of plant species.
Mass FX™’s Chlorogenin is a non-sugar saponin obtained from the California soap
plant. The plant is also known as Amole, (Chlorogalum pomeridianum) (Anderson &
Roderick, 2006; O’Neil, et al., 2006). Chlorogenin has been shown to increase weight
gain in rats (Syrov & Kurmukov, 1976). However, this anabolic effect was weakened
when the rats were castrated (Syrov & Kurmukov, 1976). This suggests that chlorogenin
might work by enhancing testosterone production on the level of the testes to produce
such an anabolic effect (Syrov & Kurmukov, 1976). Thus, this mode of action suggests
that chlorogenin is not an anabolic/androgenic steroid. If it were an anabolic steroid, its
anabolic activity would not decrease because of castration. According to Syrov &
Kurmukov (1976), chlorogenin displays anabolic activity without any androgenic
properties. Thus, it can be hypothesized to be void of negative side effects associated
with anabolic/androgenic steroids. With such anabolic properties, it is hypothesized that
chlorogenin will help in enhancing testosterone production and probably the natural
increase in testosterone production by the body in response to exercise. Therefore, the
result of its usage might increase muscle mass and exercise performance due to increased
protein synthesis in skeletal muscle tissue because of increased testosterone levels.
2. (-)-3,4-divanillyltetrahydrofuran (DVTHF)
(-)-3,4-divanillyltetrahydrofuran (DVTHF) is an extract from the stinging nettle
root (Schöttner et al., 1997). DVTHF exerts its effects by acting on testosterone transport
proteins. Testosterone in the human body exists either in a free circulating form or in
inactive form bound to transport proteins. The transport proteins to which testosterone
binds are albumin and sex hormone binding globulin (SHBG) (Neischlag et al., 2004).
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DVTHF binds with very high affinity to SHBG (Ka = 3.2 +/- 1.7 x 10(6)M-1) (Schöttner
et al., 1998). It is hypothesized that by binding to SHBG, DVTHF will increase the
concentration of free testosterone. Due to the anabolic nature of testosterone, a higher
concentration of free testosterone should translate into enhanced exercise performance
manifested by an increase in muscle mass and strength. Also, it is hypothesized that
DVTHF might positively influence body composition by increasing muscle mass and
reducing body fat levels. This positive influence on muscle tissue is due to the higher rate
of protein synthesis that occurs due to more availability of free testosterone binding to the
androgen receptors on skeletal muscle tissue. Studies have shown that DVTHF binds to
SHBG, however no studies have been conducted to show that more free testosterone will
be available.
Notable benefits associated with the plant in which DVTHF is extracted include
effective treatment protocols for benign prostatic hyperplasia (BPH) (Schöttner et al.,
1997). Another benefit of Urtica dioica extracts is its blood glucose lowering effect. It
has been used as a hypoglycemic for centuries in Persia as it has been noted in writings of
Avicenna (981-1037), a prominent Persian medical scholar (Farzami et al., 2003). Its
therapeutic blood sugar balancing effects are a result of enhancement of insulin secretion
by Islets of Langerhans (Farzami et. al., 2003) and by reduction of intestinal glucose
absorption (Bnouham et. al., 2003). In addition to its hypoglycemic effects, Urtica dioica
is used in traditional medicine to treat hypertension (Testai et al., 2002). Urtica dioica’s
antihypertensive effects are attributed to vasorelaxing effects due to an upregulation of
nitric oxide production in endothelial cells (Testai et al., 2002). Finally, Urtica dioica
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exhibits antioxidant, antimicrobial, antiulcer, and analgesic properties (Gulcin et al.,
2004).
Bioavailability and Absorption Enhancing Compounds
1. 6',7'-Dihydroxybergamottin (6,7-DHB)
The third ingredient is 6',7'-Dihydroxybergamottin (6,7-DHB). 6,7-DHB, a
furanocoumarin, is one of the many bioactive compounds found in grapefruit juice (Row
et al., 2006). 6,7 DHB has been shown to enhance the bioavailability of medications by
inhibiting Cytochrome P3A4 (Ohta et al., 2002). Cytochrome P3A4 is an enzyme
predominantly found in the liver that metabolizes various compounds such as drugs,
xenobiotics, and endogenous compounds such as steroids (Robertson et al., 2003). It has
been shown that the co-administration of 6,7DHB with a drug of interest will increase
that drug’s concentration thus enhancing its effects (Christensen, 2002). Thus, according
to the manufacturer, it is suggested that 6,7DHB might enhance the bioavailability of its
anabolic ingredients.
2. Bioperine®
The final ingredient in Mass FX™ is Bioperine®. Bioperine® is a patented
extract (US Patent# 5,536,506) from the black pepper plant. Bioperine® is used to
increase the bioavailiabilty of nutritional compounds (Sabinsa, 2005). To illustrate this,
clinical studies have shown that the co-administration of Bioperine® with coenzyme q10,
beta carotene, and curcumin increased bioavailability by 30%, 60% and 2000%
respectively (Badmaev et. al., 2000; Badmaev et al., 1999; Shoba et al., 1998). In Mass
FX ™ and according to the manufacturer, the addition of Bioperine® is suggested to
enhance the absorption of chlorogenin and DVTHF.
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Potential Benefits
Supplementation with Mass FX™ may provide a safe and natural alternative to
illegal and unethical methods (Anabolic/Androgenic steroids) to enhance testosterone
changes for athletes who train intensely and are at risk of overtraining.

Muscle Hypertrophy
The process of muscle hypertrophy is mediated by various genetic expressions of
contractile and metabolic changes in muscle due to exercise (Borer, 2003, p.129). During
exercise, the stretch of contractile proteins within skeletal muscles induces a cascade of
transcriptional and translational growth signals including expression of myogenic
regulatory factors and satellite cell proliferation, which in turn promotes hypertrophy by
fusing with existing muscle fibers. Not only is muscle growth regulated process that
induce muscular stretch, it is also induced by extra force loading such as weight training.
Loading causes the down-regulation of a specific growth factor called myostatin.
Myostatin is a inhibitor of muscle growth, thus its subsequent down-regulation due to
exercise will result in a favorable environment for muscle growth (Borer, 2003, p.130).
Finally, skeletal muscle hypertrophy can be induced by increases in testosterone levels
(Borer, 2003, p.130).
Testosterone and Resistance Training
Testosterone concentrations change in response to acute and chronic training.
Acute training responses refer to the responses that occur immediately after a single bout
of exercise. On the other hand, chronic training responses refer to the responses that
occur after progressive bouts of exercise over a specific period (i.e. weeks or months).
Acute resistance training has been shown to cause a release of androgens including the
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anabolic hormone testosterone, which persists for up to 20 minutes post a single bout of
resistance training (Kraemer & Ratames, 2005). It has been suggested these acute
responses appear to be vital in the muscle adaptive process that lead to tissue growth.
Conversely, chronic training doesn’t increase basal testosterone concentrations (Kraemer
& Ratamess, 2005). There are multiple hypotheses explaining the cause of these
elevations. One explanation could be due to decreases in steroid metabolism in the liver
due to reduced hepatic flow during exercise (Borer, 2003, p.168). Another explanation
for increased testosterone levels may be attributed to the evidence showing that both
testosterone and catecholamine concentration increases are directly proportional to
exercise intensity. Thus, it has been hypothesized that sympathetic nerve activity and
catecholamine release may induce testosterone elevations (Borer, 2003, p. 168). Further
studies are required to confirm and elucidate these mechanisms in detail.
Testosterone Mode of Action on Skeletal Muscle
Sinha-Hikim et al. (2002) have shown that increases in muscle volume in
response to graded testosterone levels was due to increases in muscle fiber type 1 and 2
cross-sectional area, satellite cells and myonuclear number in a dose dependent fashion.
In addition, testosterone supplementation in a nutrient deprived state stimulates synthesis
of skeletal muscle proteins and reduces breakdown (Ferrando et al., 1998). To illustrate
the hypertrophic effects of testosterone, exogenous testosterone supplementation in
healthy and diseased subjects resulted in anabolic activity including increases in strength
and muscle mass (Bhasin et al., 1996; Bhasin et al., 2001; Knapp et al., 2008).
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Summary
This chapter discussed the Mass FX™ formulation with a detailed review
regarding its ingredients. The possible potential benefits of this product were also
discussed. Finally, this chapter concluded with a brief explanation of the muscle
hypertrophy process, testosterone in relation to exercise, and testosterone’s influence on
skeletal muscle.

\
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CHAPTER III
METHODS
This chapter will discuss the overall hypothesis and methodology utilized for the
study. This chapter will also discuss data gathering, recruiting, instrumentation, protocol
procedures and design analysis. This chapter will be concluded by a summary of the
methodology and protocols performed for the study.
Overall Hypothesis
It is hypothesized that the characteristic composition of Mass FX ™, a dietary
supplement that enhances testosterone utilization, will improve muscular strength, body
composition (increase in muscle mass), and free and total testosterone with no significant
changes in selected clinical health markers (See appendix F).
Setting
This study was conducted at a university fitness center in a Mid-Western state.
The university serves nearly 17,000 students, and offers more than 100 undergraduate
and 50 Ph.D., graduate, and professional degrees.
Human Subjects Consideration
Human subjects have several rights when participating in a research study. These
rights include the right to self-determination, the right to privacy, the right to
confidentiality, the right to fair treatment, and the right to protections from pain,
discomfort, or other harm (Burns and Grove, 2004).
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Subject Recruitment
A sample of “apparently healthy" young males between 21-32 years of age from
Wright State University were recruited to participate in the study. The participants were
recruited by referral from employee’s at the local fitness center who discussed the study
to regular patrons. If interested, volunteers were instructed to discuss the study further
with the primary investigator (Mr. Patrick Dib). Participants who decided to be a part of
the study were instructed to set up an initial screening appointment to determine their
eligibility for the study at the Exercise Biology Laboratory at Wright State University. To
be included in the study, subjects had to be young males aged 21-35 years of age with
weight lifting experience of at least six months and with no current disease.
Eligibility Determination
To insure that the participants were “apparently healthy,” an AHA/ACSM
Health/Fitness Facility Preparticipation Screening Questionnaire (Appendix A) was
completed prior to engaging in this study.
Participants who exhibited no more than one coronary artery disease risk factor
and no signs/symptoms of metabolic, musculoskeletal, endocrine, or cardiopulmonary
disease were considered apparently healthy in accordance with current American Heart
Association / American College of Sports Medicine (ACSM) guidelines (ACSM, 2006,
p.25). If warranted, subjects were asked to obtain medical clearance from their
supervising physicians.
Informed Consent
The primary investigator (Mr. Patrick Dib) fully explained the procedures and
methodology involved for the study. Mr. Dib also answered all questions that the
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participants had after receiving approval from Wright State University’s Institutional
Review Board. Furthermore, each subject who agreed to participate in the study
voluntarily signed an informed consent (Appendix B). Before signing the consent, the
subjects were informed that their participation was voluntary and that they reserve the
right to withdraw at any time without any penalty.
Risks
The following risks were noted for this study.
1. Increased testosterone levels may cause acne, oily skin, increased body hair,
minor hair shedding, and gynecomastia.
2. Venipuncture may cause a slight bruise and minor pain.
3. Although the study subjects will be well trained in muscular strength exercises,
there may be some minimal muscle soreness 24 hours posttesting due to high
subject motivation.
4. Muscular injuries may result from training and testing.
Randomization of Subjects
After taking all the necessary pre-study measurements, subjects were divided
randomly into two different groups using a web-based randomizer application
(http://www.randomizer.org/). The randomizer was utilized by an undergraduate
assistant (UA). The UA assigned each subject a number from one to twelve in which was
entered in the application. The UA set the application to output six random numbers from
the 12 originally entered. The six numbers that were released designated group one,
which represented the subjects who will supplement with Mass FX. The remaining six
numbers belonged to group two which supplemented with the placebo. Both groups were
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then given the protocol of supplementation, exercise, and diet. The supplements were
distributed in a double blind manner.
Subject Safety
Subjects were monitored at every workout session by the primary investigator or
trained and designated senior exercise biology student to ensure all safety precautions are
followed. In addition, the subjects were contacted daily to determine problems or unusual
symptoms that may arise.
Subjects were all healthy and without any known current disease. They were not
taking any other nutritional supplement, ergogenic aid, and/or drug. The only permitted
supplement was pure whey protein powder containing no additional ingredients. This was
done to ensure that the subjects met their protein requirements. Subjects refrained from
alcohol throughout the study.
Exclusion Criteria
The exclusion criteria included males younger than 21 years of age, with current
medical disease, taking current medication, and/or with weight lifting experience of less
than six months. In addition, any subject with significant anomalies observed during
initial blood testing by the official medical supervisor, Dr. Corey Ellis and/or the primary
investigator, Mr. Patrick Dib, were excluded. Finally, any subject who failed to comply
with diet, nutrition, and/or supplementation were immediately withdrawn from the study.
Diet
Subjects’ total caloric intake and macronutrient breakdown was determined by
incorpporating a diet utilized commonly by bodybuilders. Each subject had his own
custom diet based on bodyweight. First, baseline calories were determined for each
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subject by multiplying his total body weight in pounds by 14. The number obtained was
considered the baseline caloric intake in kcals. Then, 500 kcals was added to the baseline
caloric value. This was done to ensure that subjects were consuming enough calories to
promote exercise recovery and hypertrophy. The obtained total caloric intake was then
distributed specifically amongst protein, carbohydrates, and fats.
Protein intake in grams per day was determined by multiplying 1.2 to the body
weight in pounds of the subject. Then, this value was multiplied by 4 to determine protein
calories from the total calories that were calculated initially.
Fat intake was set to be 25 % of total caloric intake. To determine the fat caloric
amount in grams, the caloric value of fat was divided by 9.
The calories that remained from subtracting the combination of protein and fat
calories were those of carbohydrates. To determine the carbohydrate caloric amount in
grams, the caloric value of carbohydrates was divided by 4 (See Appendix C).
Subjects were instructed to log their nutritional and supplement intake in a
journal. Also, they were advised to use the USDA National Nutrient Database for
Standard Reference website part of the department of agriculture to determine the caloric
value of their meals (http://www.nal.usda.gov/fnic/foodcomp/search/) (Nutrient data
laboratory, 2008). The subjects were instructed to provide the primary investigator with
copies of the journal on a weekly basis to determine compliancy. This enabled the
primary investigator to review each log for each subject weekly. During the review, the
primary investigator noted whether the subject was consuming the recommended calories
and macronutrient recommendations.
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Supplementation
To prevent observer bias, the study was conducted in a double-blind fashion. The
primary investigator was not aware supplement distribution and group membership of
each subject. Mass FX and placebo were administered to the subjects by the director of
the exercise biology lab, Dr. Pohlman who kept the record of distribution. In addition,
each subject was instructed to consume four pills/day as recommended by the
manufacturer on the bottle regardless of bodyweight (See Appendix C). Both the actual
supplement and placebo were provided by Anabolic Xtreme (Anabolic Xtreme, Tempe,
AZ). Both pills were packaged exactly the same. They shared the same geletin capsule
size, color, and outside labeling. Bottles were distinguished only by Dr. Pohlman via
record of lot numbers. A certificate of analysis for the specific batch of Mass FX used in
this study was provided to determine that the ingredients met with label claims. Placebo
pills contained only rice flour and the gelatin from the capsule itself. At the end of the
trial, Dr. Pohlman provided the primary investigator with the record of distribution. In
turn, this enabled the primary investigator to analyze the results with the appropriate
statistical tests.
Exercise Training Protocol
All subjects followed the same resistance training protocol. The resistance
training protocol used in this study was an upper/lower body split (See Appendix D)
regimen with cardiovascular work on nonresistance training days. The subjects had only
one full rest day during each week. The subjects performed the upper/lower training split
twice a week with 48 hours in between each session. The rationale behind this frequent
training is that there is evidence suggesting that there is a greater summation of myogenic
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responses that might lead to better muscle hypertrophy responses (Haddad & Adams.,
2002). Not only that, but after a resistance training bout there are increases in muscle net
protein balance for up to 48 hours (Phillips et al., 1997). Therefore, it is hypothesized that
the frequent training (48 hours between sessions during a week) in this study might
further enhance the muscle net protein balance increases, which might subsequently lead
to better muscle hypertrophy. In addition to resistance training, endurance training was
performed to enhance insulin sensitivity via upregulation of the glucose transporter
protein, GLUT-4 (Hardin et al., 1995). Subjects performed 30 minutes of low intensity
endurance training. This was done in efforts to improve nutrient partitioning towards
muscle tissue.
Pretesting
Demographics and Anthropometric Measurements
After signing the informed consent, demographic information regarding each
subject was collected. This information included the subject’s name, date of birth, height,
weight and body fat (Appendix E). In addition, each subject was assigned an ID number,
which was used during result analysis to maintain confidentiality of subject data.
Stature was measured without shoes and socks to the nearest 0.1 inch using a
stadiometer (SECA, 2006, Germany). Prior to taking the measurement, it was assured
that the individual’s weight was equally distributed through both feet with heels together
and arms at the sides of the trunk. The subjects were instructed to keep their heads in
level with the eyes fixed straight ahead in a Frankfort plane position.
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Body Composition
Body fat and weight was measured via a recently calibrated BOD/POD (Life
Measurement Inc., Concord, CA). To do so, the subjects wore spandex or compression
shorts and removed all jewelry and accessories. In addition, the subjects were given a
Speedo© head cap to cover their hair. This is done in order to make sure that no air is
trapped in the hair. Also, the subjects refrained from eating, drinking, and exercising for 2
hours before the test.
The BOD/POD utilizes air displacement to produce its results. It is a very
convenient way of assessing body composition in comparison to other techniques such as
skin fold calipers, bioelectrical impedance, hydrostatic weighing, and DEXA (Duel
Energy X-Ray Absorptiometry) for various reasons. First, it is very user friendly: the
subject sits in relaxed manner inside the machine; the procedure doesn’t involve exhaling
air out of the lungs underwater (compared to hydrostatic weighing) and it doesn’t involve
radiation (compared to DEXA). Secondly, it has a much lower error rate (+2%) (Life
Measurement Inc., 2006). Other methods, such as BIA and skinfold calipers, may have a
6-8% error range (Life Measurement Inc., 2006). Finally, it reproduces results in a time
efficient fashion, usually 5-8 minutes with minimum disturbances to the subject. Skin
pinching, holding the breath, pressing buttons, and radiation exposure are not an issue
with a BOD/POD.
Blood Chemistries
After gathering demographic and body composition data, blood samples were
drawn to analyze blood chemistries prior to the start of study. Blood was drawn by a
certified phlebotomist from LabCorp (Laboratory Corporation of America, 3291 Seajay
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Dr, Beavercreek, OH 45430). Serum testosterone concentrations exhibit diurnal variation
(Diver et al., 2003) (See Figure 2). Studies have shown that testosterone concentrations
peak in the morning at 0700hrs (Walton et al., 2007) reaching their lowest concentration
in the early evening at 1900 h (Walton et al., 2007). Due to these findings, the blood tests
were performed first thing in the morning after an overnight fast of 12 hours. This was
performed in order to determine the testosterone concentrations at its peak concentrations
and for consistency in measurements.

Figure 2: Diurnal variation in testosterone concentrations (Diver et al., 2003).

In addition, subjects refrained from alcohol, sexual activity, intense physical
activity, OTC medications, and exercise two days before the blood draw. The
phlebotomist took approximately three vials of blood from the antecubital vein. Then, the
samples were subsequently analyzed by LabCorp for the following markers:
1. Complete blood count: white blood cell count (WBC), white blood cell
differential: (neutrophils lymphocytes, monocytes, eosinophils, basophils,),
absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute
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eosinophils, absolute basophils, red blood cell count (RBC), hemoglobin (Hb),
hematocrit (Hct), platelet count, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration
(MCHC), red cell distribution width (RDW).
2. Lipid Profile: Low density lipoprotein (LDL), High density lipoprotein (HDL) ,
Very low density Lipoprotein (VLDL), Triglycerides (TG), Total cholesterol
(TC).
3. Hepatic: Alkaline phosphatase (ALP), Aspartate aminotransferase (AST),
Alanine aminotransferase (ALT)
4. Renal: Creatinine, Blood Urea nitrogen (BUN)
5. Serum Steroids: Total and free testosterone.
Total and free testosterone analyses are usually performed to determine gonadol
function (Bishop et al., 2005, pg 438). In this study, these tests will determine if Mass FX
enhances testosterone production in the body. Free testosterone measurement refers to the
measure of testosterone that is not bound to any transport proteins (Bhasin et al., 1998).
Total testosterone measurement refers to the measure of free plus protein bound
testosterone.
The liver enzymes alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) are measured to determine if there are any hepatic complications.
Elevations in both AST and ALT indicate hepatocellular injury (Gail, 1999, p. 178).
Alkaline phosphatase is measured to determine if there is any bile flow impairment,
development of space occupying lesions, cholestasis, and other conditions including but
not limited to viral hepatitis and hepatic lipidosis. (Gail, 1999, p. 182). The renal marker,
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creatinine, is tested to determine any renal complications such as decreased glomerular
filtration rate. It is also tested to determine any skeletal muscle myopathy (Gail, 1999, p.
59). The second renal marker, blood urea nitrogen (BUN), is usually tested to determine
if there is any chronic glomerulonephritis, pyelonephritis, and other chronic kidney
diseases (Gail, 1999, p. 60). Complete blood count with differential analysis is usually
performed to detect anemia, evaluation of inflammation, infections and peripheral blood
characteristics, and polycythemia evaluation (Gail, 1999, p. 71). In the blood complete
blood count analysis, the red blood cell indices, RDW (Red cell distribution width), MCV
(Mean corpuscular volume), MCH (Mean corpuscular hemoglobin), and MCHC (Mean
corpuscular hemoglobin concentration were studied. Briefly, MCV denotes the size or
volume of the erythrocyte. MCH denotes the weight of the hemoglobin in the average
erythrocyte. MCHC refers to the amount of hemoglobin present in the average red cell as
compared to its size. Finally, RDW refers to erythrocyte size variability (Jacobs et al.,
1996, p. 344). Measuring red blood cell indices offer a quick and efficient method to
determine hematological abnormalities such as anemia, iron deficiency, spherocytosis
(sphere-shaped erythrocytes), folate deficiency, vitamin B12 deficiency, vitamin B6
deficiency, and thalassemia (Jacobs et al., 1996, p. 343). As for immune function, the
absolute and percentage number of leuckocytes were measured. Absolute values denote
the absolute count of the leukocytes: neutrophils, lymphocytes, monocytes, eosinophils,
and basophils, respectively. The absolute counts are calculated by multiplying the
percentage of each type of leukocyte by the total white blood cell count. Finally, lipid
profile analysis measures total cholesterol, low density lipoproteins, and high density
lipoproteins to evaluate cardiovascular risk factors (Bishop et al., 2005 p.282).
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Muscle Strength Testing
The subjects were instructed to return to the Exercise Biology laboratory two days
after the blood sampling to determine their muscular strength. Prior to assessing
performance, the subjects were asked to warm-up for 10 minutes by performing light
aerobic activity (fast walking on a treadmill) and dynamic stretches. After warming up,
the subjects performed the three designated lifts required for the study: bench press,
deadlift, and leg press.
Each activity is unique because each lift tests different muscle groups and
different muscular skills. The rationale behind using three different exercises instead of
one is because there is no single known exercise that tests for whole body strength.
Instead, testing via a variety of exercises that focus on one area of the body at a time will
produce accurate results in determining exercise performance improvements.
The first lift performed was the bench press. The bench press is a lift that focuses
on upper body strength since it predominantly utilizes the pectoralis major, anterior
deltoid, and the triceps to perform work (Aaberg, 1999 p.154).
The second lift is the deadlift. The deadlift can be considered as an exercise that
utilizes both upper body and lower body muscles manifest by utilization of the leg muscle
as well as the abdominals (core muscles) trapezius, and the rhomboids (upper back
muscles). The deadlift is considered one of the best exercises for body strength (Groves,
2000 p.41). Along with the bench press, it is included in powerlifting competitions
(Groves, 2000 p.31, 41).
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The third and final exercise is the leg press. The leg press test is a measure of
lower body strength. The muscle fibers that are recruited to perform the work are the
gluteus maximus and minimus, hamstrings, and the quadriceps. It is a very efficient and
safe exercise since it stabilizes the body in a fixed position thus reducing the risk of back
and spinal injury in comparison to other compound leg exercises such as the squat
(Aaberg, 1999 p.130).
All these lifts were performed in a 1 Repetition Maximum (1-RM) manner. 1-RM
tests are performed in a gradual fashion with added weight on each trial until the subject
cannot perform a complete lift. Each subject initially started with a low weight. If the
subjects can perform the lift properly, five pounds were added to the next attempted lift.
This continued until the subject could no longer lift the specified amount of weight. The
last amount of weight used in which the subject performed a complete full repetition was
considered their one repetition maximum. During these tests, a spotter was available to
minimize the risk of injury and to ensure the proper execution of the exercises. The
spotter only helped when the weight was moving down towards (down) the subject, not
when moving away (up).
Posttesting
After the successful completion of the allocated six week study, the pre-testing
measurements: body composition, blood chemistries, and muscular strength were
repeated in order to determine any changes that may have occurred as a result of
supplementation.
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Design and Analysis
The design of the study was of a Pretest-Posttest Control group design. The
experimental and control groups were randomly assigned. To prevent observer bias, the
study was conducted in a double-blind fashion. The primary investigator was not aware
of the distribution of supplements and or group membership. The supplements and
placebo were administered to the subjects by Dr. Pohlman who kept the record of
distribution. In addition, the subjects were instructed to consume 4 pills/day (See
Appendix C). Both the actual supplement and placebo were provided by Anabolic
Xtreme. Both pills were packaged exactly the same. They shared the same pill size, color,
and outside labeling. Bottles were distinguished only by Dr. Pohlman via record of lot
numbers.
All statistical analyses were performed at Wright State University’s statistical
consultation center. Results were analyzed by Analysis of Covariance (ANCOVA), using
Group as the independent binary variable (binary value having 2 levels: Mass FX™
[MFX] or Placebo [P] and the corresponding pre-treatment variable as the covariate. Due
to the number of variables, the ANCOVA with a Bonferroni correction was initiated
resulting in a family-wise level of significance of α = 0.05, to avoid inflation of the Type
I error. To confirm results, an independent samples t-test using a Bonferroni correction
with a family-wise level of significance of α=0.05 was performed.
Summary
This chapter described the methods that were used in this study. A sample of
“apparently healthy” young males was recruited through learning about the study at the
university’s local fitness center. Demographics were taken first, followed by other study32

specific measurements (body composition, 1-RM muscle strength, and blood
chemistries). After obtaining the required measurements, the subjects received the
supplements and placebo depending on the group to which they were randomly assigned.
A workout program was provided and used in conjunction with the supplementation for
six weeks. After six weeks, the subjects were retested again to determine any changes in
body composition, exercise performance, and blood chemistries. All data gathered from
the pre- and posttrial testing dates were recorded and analyzed to determine significant
changes in the aforementioned variables due to supplementation with Mass FX.
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CHAPTER IV
The aim of this chapter is to present all the data gathered in this trial. In addition,
this chapter will reveal the statistical analysis performed to draw conclusions based on
the hypotheses presented in Chapter I. Finally, this chapter will end with a summary of
the major findings in this trial.
Results
The subjects’ mean age was 25 + 3.02 years. Their mean height was 70 inches +
3.07 (177.8 centimeters + 7.79). Their body weight before and after the trial was 186.17
pounds + 28.13 (84.23 kilograms + 12.72) and 187.38 pounds + 30.16 (84.78 kilograms +
13.64), respectively. All eight subjects had at least two years of weight training
experience. They completed the trial successfully with full compliance to testing, diet,
training, and supplementation. The subjects kept records of diet and supplementation and
shared them with the primary investigator each week
The study started with six adult males in each of the treatment and control groups,
but four of the participants failed to follow the study guidelines and were omitted from
the final analyses. Four participants in each group remained.
To analyze the results, the data from both groups were separated into two
categories: Primary outcomes and Secondary outcomes. The Primary outcomes data set
included total and free testosterone, bench press, deadlift, leg press, fat mass, and fat free
mass values. The Secondary outcome data set included the selected clinical health
markers. (See Appendix F). All analyses were conducted using statistical software
package SPSS 16.0.
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Primary and Secondary outcomes were analyzed by Analysis of Covariance
(ANCOVA), using Group as the independent binary variable and the corresponding pretreatment variable as the covariate. Specifically, the Group variable represents group
membership to either Mass FX or Placebo. On the other hand, the pretreatment variable
represents the initial values to the parameters being studied prior to exercise and
supplementation with either Mass FX or Placebo. Because of the multiple hypotheses
being tested, a Bonferroni correction with a family-wise level of significance of α = 0.05,
was used when determining which ANCOVAs were significant in each family of tests.
To confirm results, an independent samples t-test using a Bonferroni correction with a
family-wise level of significance of α=0.05 was performed
Method of Analysis
Using ANCOVA the Post-value was modeled on group and pre-treatment values.
This was done to determine if Group affects the post value after adjusting for the Prevalue. Using the independent samples t-test, the outcome was modeled to be the
difference between pre and post values.
Primary Outcomes
The variables of Group and the corresponding Pre-treatment measure were not
sufficient (p>0.05) to explain the variance in outcomes for total testosterone and free
testosterone (See Table 20). In this case, statistical conclusions can not be made. On the
other hand, the other five ANCOVA models run (bench press, deadlift, leg press, fat
mass, and fat free mass values) were significant and warranted further examination (See
Table 20). For all five of these models, the pretreatment variable was significant
(p<0.05), indicating that it was useful to include it as a covariate (See Table 20).
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After adjusting for pretest bench press values, the two study groups showed a
statistically significant difference in the mean bench press weight (p=0.019). The mean of
the Mass FX group (mean = 15.27 kilograms) was greater than the Placebo (mean= 1.69
kilograms). Therefore, the Mass FX group, on average, was lifting statistically
significantly heavier weights than their placebo counterparts were. Group membership
was not significant for Leg Press, Dead Lift, Fat Free, and Fat Mass. This suggests that
for these variables associated with Primary outcomes most of the variance was due to the
pretreatment variables (p<0.05) and not the group variable (p>0.05). In this case, it is
suggested that exercise, not supplementation was a major factor in explaining the
variance of these outcomes. In detail the findings of the primary outcomes were:
•

Bench press – the model was significant (p = 0.000), and the adjusted R2 = 0.966
suggests that the variables Group and Pre-bench explain about 96% of the
variation in the outcome Post-bench. The Group membership variable was
significant in this case (p = 0.019). The estimate of the beta coefficient = -32.323.
This means that the mean value of the Bench Press outcome was on average about
32 pounds (or 14.65 kilograms) lower for the Placebo group when compared with
the Mass FX treatment group, after adjusting for weight that was bench-pressed
prior to the intervention.

•

Leg press – the model was significant (p = 0.000), and the adjusted R2 = 0.942
suggests that the variables Group and Pre-Leg explain about 94% of the variation
in the outcome Post-Leg. The group variable was not significant (p = 0.134).

•

Deadlift – the model was significant (p = 0.000), and the adjusted R2 = 0.934
suggests that the variables Group and Pre-deadlift explain about 93% of the
36

variation in the outcome Post-deadlift. The group variable was not significant (p
= 0.284).
•

Fat free mass– the model was significant (p = 0.000), and the adjusted R2 = 0.991
suggests that the variables Group and Pre-fat free mass explain about 99% of the
variation in the outcome Post-fat free mass. The group variable was not
significant (p = 0.215).

•

Fat mass – the model was significant (p = 0.000) and the adjusted R2 = 0.972
suggests that the variables Group and Pre-fat mass explain about 97% of the
variation in the outcome Post-fat mass. The group variable was not significant (p
= 0.955).
Secondary Outcomes
The remaining variables, the secondary outcomes (See table 21), were of interest

only in verifying that there was no change from pre- to posttraining for these measures.
The same type of model (ANCOVA) was used for these variables as for the primary
variables of interest.
In all secondary outcomes, the outcome was not significantly affected by the
Group variable (all p>0.05) (See Table 21). Therefore, it is suggested that
supplementation does not affect these health markers.
It was noted that the ALP and Platelet count outcome models were significant at
the family-wise level of significance α = 0.05 using a Bonferroni correction at the Pretreatment variable level (See Table 21), but any changes were considered due to changes
from pre-treatment values and not due to supplementation (Group variable p>0.05).
However, despite changes, all values remained within the normal ranges.
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Strength Test
As mentioned earlier, both groups had significant improvements in all three
strength tests (Model significance p<0.05) However, the bench press outcome had a
group variable of p<0.05 suggesting that Mass FX supplementation had a role in this
improvement.
To reiterate, all subjects using Mass FX showed strength improvements in all
three lifts in comparison to their pre-trial values. Of all three strength parameters, only
the bench press differences were statistically significant between the two groups (See
Table 1). The Mass FX group exhibited a mean increase of 15.27 kilograms between preand post test whereas the Placebo’s mean difference increase was 1.69 kilograms from
pre-trial testing (See Figure 3). The percent difference between both groups was
calculated to be 800 %. For the deadlift, the Mass FX group exhibited a mean difference
increase of 15.8 kilograms whereas the Placebos mean increase was 7.91 kilograms (See
Figure 4). The deadlift percent difference between both groups was calculated to be 100
%. Finally, for the leg press, the mean increase was 48.07 kilograms for Mass FX
whereas the change in Placebo was 13.57 kilograms (See Figure 5). The leg press percent
difference between both groups was calculated to be 254.16 %.
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Table 1
Muscle Strength for Mass FX Group (kg) a
Subject

Bench Press

Leg Press

Pre

Pre

Post

Deadlift
Post

Pre

Post

MFX1

110.85 124.43 348.41 409.50

MFX2

117.64 142.53 470.58 552.03 183.25 205.88

MFX3

119.90 128.95 429.86 452.48 165.15 174.20

MFX4

110.85 124.43 429.86 457.01 138.00 156.10

Mean

114.81 130.09 419.68 467.76 157.23 173.07

S.D

4.66

a

8.56

51.24

60.12

142.53 156.10

21.02

23.47

Notes: Comparison of Mass FX pre/post results of the 1‐RM max test

Table 2
Muscle Strength for Placebo Group (kgs) a
Subject

Bench Press

Leg Press

Pre

Pre

Post

Pre

Post

Deadlift
Post

PL1

88.23 88.23

266.96

266.96

124.43 124.43

PL2

138.00 138.00 429.86

429.86

151.58 165.15

PL3

56.56

61.08 257.91

289.59

83.71

PL4

88.23

90.49 266.96

289.59

124.43 124.43

Mean

92.76 94.45

305.42 319.00

121.04 128.95

S.D

33.65 31.96

83.06

27.98

a

74.67

101.80

26.38

Notes: Comparison of Placebo pre/post Results of the 1‐RM max test
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Mean increase in weight lifted (kilograms)

Post Trial Bench Press Changes
20

*

15
10
5
0
Mass FX

Placebo

Group

Mean increase in weight lifted (kilograms)

Figure 3: Comparison of mean Bench Press changes between Mass FX and Placebo.
*p=0.019

Post Trial Deadlift Changes
20
15
10
5
0
Mass FX

Placebo

Group

Figure 4:Comparison of mean Deadlift changes between Mass FX and Placebo.
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Mean increase in weight lifted (kilograms)

Post Trial Leg Press Changes
80
60
40
20
0
Mass FX

Placebo

Group

Figure 5: Comparison of mean Leg Press changes between Mass FX and Placebo.

Body Composition
Significant improvements in body composition were reported in both Mass FX
and Placebo groups (Model significance p<0.05). However, the Mass FX group exhibited
better improvements (Table 3); yet, these changes could not be attributed to
supplementation (Group significance p>0.05). Mass FX’s mean lean mass (fat free mass)
increase was 2.26 kilograms, whereas the Placebo subjects mean increase was 0.98
kilograms (See Figure 6). The percent difference between the groups was calculated to be
134.48 %. Regarding fat mass, Mass FX had a small improvement over the Placebo
group. Mass FX had a mean reduction of 1.09 kilograms of body fat while the placebo
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had a mean reduction of 1.05 (See Figure 7). The percent difference of this parameter

Mean increase in fat free mass (kilograms)

between Mass FX and Placebo was calculated to be 4.301 %.

Post Trial Fat Free Mass changes
4
3
2
1
0
Mass FX

Placebo

Group

Figure 6: Comparison of mean Fat Free Mass gains between Mass FX and Placebo
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Mean decrease in fat mass (kilograms)

Post Trial Fat Mass Changes
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
Mass FX

Placebo

Group

Figure 7: Comparison of mean Fat Mass loss between Mass FX and Placebo

Table 3
Body Composition Changes a

Subject

Fat Free Mass (kgs)

Fat Mass (kgs)

Pre

Post

Pre

Post

MFX1

73.30

76.06

9.00

8.95

MFX2

76.19

80.18

25.42

24.34

MFX3

73.07

74.38

10.22

8.95

MFX4

70.04

71.04

17.10

15.11

Mean

73.15

75.41

15.44

14.34

S.D

2.51

3.80

7.55

7.27

PL1

59.32

59.72

27.28

28.95

PL2

80.63

82.03

15.61

14.38

PL3

44.66

46.28

14.66

12.76

PL4

69.18

69.68

8.05

5.29

Mean

63.45 64.43

16.40 15.35

S.D

15.25 15.15

7.99

a

9.89

Notes: Pre‐ and post‐changes in fat free mass and fat mass in Mass FX (MFX) and Placebo (PL)
groups
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Renal Function
Renal function was assessed by testing for creatinine and blood urea nitrogen
(BUN) levels (Tables 4 and 5).Unlike BUN, creatinine exhibited a Model p value <0.05.
However, it was not considered a significant model after applying the Bonferroni
correction. Supplementation with Mass FX did not affect these markers (Group variable
p>0.05).

Table 4
Renal Values for Mass FX Group (mg/dl) a
Subject

Creatinine

BUN

Pre

Post

Pre

Post

MFX1

1.1

1.2

21

22

MFX2

1.1

1

19

12

MFX3

1.1

1.3

25

18

MFX4

0.8

0.7

21

15

Mean

1.025 1.05

21.5

16.75

S.D

0.15

2.51

4.27

0.26

a

Notes: Comparison of Mass FX pre/post Results of renal function test. Reference ranges for Creatinine
are 0.5‐1.4 mg/dl. Reference ranges for BUN are 3‐29 mg/dl. Ranges provided by Compunet Labs
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Table 5
Renal Values for Placebo Group (mg/dl) a
Subject

Creatinine

BUN

Pre

Post

Pre

Post

PL1

1

1.1

14

19

PL2

1.3

1.2

15

17

PL3

0.8

0.8

15

20

PL4

1.1

1.1

16

20

Mean

1.05

15

1.05

19

S.D

0.20

0.81

0.17

1.41

a

Notes: Comparison of placebo pre/post results of renal function test. Reference ranges for
Creatinine are 0.5‐1.4 mg/dl. Reference ranges for BUN are 3‐29 mg/dl. Ranges provided by
Compunet Labs

Serum Steroids
As mentioned earlier, the variables of group and the corresponding pretreatment
measure were not sufficient to explain the variance in outcomes for total testosterone
(p=0.619) and free testosterone (p=0.076). In this case, statistical conclusions can not be
made. However, improvements were observed, as it was apparent that the Mass FX group
had higher free testosterone levels than recorded at initial testing. In, addition, the
Placebo’s free testosterone levels decreased from pre- to post-testing trial measurements.
For total testosterone, the Mass FX group exhibited a mean increase of 98.75
ng/dl between pre- and posttesting. On the other hand, the placebo group exhibited a
mean decrease of - 189.5 ng/dl from pretrial testing (see Figure 8).
For free testosterone levels, the Mass FX group exhibited a mean increase of
46.35 pg/ml between pre- and posttesting. Surprisingly, the Placebo group exhibited a
mean decrease of -41.1pg/ml from pretrial testing in free testosterone concentrations (See
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Figure 9). Despite the differences from pre- to posttesting in both groups for total and
free testosterone, values remained within the reference ranges (See Tables 6 and 7).
The results of the independent sample t test suggested that there are statistically
significant differences for the free testosterone outcome between the two groups
(p=0.001)

Table 6
Serum Steroids for Mass FX Group a
Subject

Total Test (ng/dl)

Free Test (pg/ml)

Pre

Post

Pre

Post

MFX1

222

484

43.7

115.2

MFX2

461

448

94.1

148.5

MFX3

372

546

75.6

109.7

MFX4

424

396

75.9

101.3

Mean

369.75 468.5

72.32 118.67

S.D

105.04 63.04231

20.95 20.68

a

Notes: Comparison for Mass FX pre/post results on serum steroids. Reference ranges provided by
compunet: total testosterone: 250‐1100 ng/dl; free testosterone: 35‐155 pg/ml
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Table 7
Serum Steroids for Placebo Group a
Subject

Total Test (ng/dl)

Free Test (pg/ml)

Pre

Post

Pre

Post

PL1

507

339

128

87.4

PL2

497

503

109

91

PL3

664

534

181.1 115.1

PL4

1024

558

126

Mean

673

483.5

S.D

246.18 98.92

86.2

136.02 94.92
31.23 13.60

a

Notes: Comparison for placebo pre/post results on serum steroids. Reference ranges provided by
compunet: total testosterone: 250‐1100 ng/dl; free testosterone: 35‐155 pg/ml

Post Trial Total Testosterone Changes
Mean Change in ng/dl

200
100
0
-100

Mass FX

Placebo

-200
-300

Group

-400
Figure 8: Comparison of mean changes in Total Testosterone between Mass FX and Placebo.
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Post Trial Free Testosterone Changes

Mean Change in pg/ml

100

*
50
0
Mass FX
-50

Placebo

Group

-100
Figure 9:Comparison of mean changes in Free Testosterone between Mass FX and Placebo.
*: p=0.001

Hepatic Function
Hepatic function was assessed by testing for alkaline phosphatase (ALP),
Aspartate transaminase (AST) and alanine transaminase (ALT). All markers remained
within the reference ranges except for one subject (MFX2) who had an elevated
pretesting value for both AST and ALT that was also observed in post-testing (See Tables
8 and 9). Hence, this anomaly was independent of supplementation. A model p value of
<0.05 was observed for all hepatic markers AST, ALT, and ALP. However, the changes
in ALT and AST were not considered significant models after applying the Bonferroni
correction. Both ALT and AST values remained within the normal ranges except for
(MFX2). On the other hand, the ALP changes were considered significant at the familywise level of significance α = 0.05 using a Bonferroni correction at the pretreatment
variable level. Despite these significant changes, the ALP values remained within the
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reference ranges and are not attributed to supplementation (Group variable p>0.05). This
change is not attributed to Mass FX supplementation (Group variable p>0.05), but is due
to changes from pre-treatment values. In addition, Mass FX did not affect ALT and AST
values (Group variables p>0.05).

Table 8
Hepatic Values for Mass FX Group (U/L)a
Subject

ALP

AST

ALT

Pre

Post

Pre

Post

Pre

Post

MFX1

77

73

28

32

28

29

MFX2

101

87

28

21

47

24

MFX3

58

66

50b 53b

92 b 109b

MFX4

70

69

35

42

Mean

76.5 73.75

35.25 33.5

52.25 49.75

S.D

18.11 9.28

10.37 13.77

27.69 39.86

28

a

37

Notes: Comparison for Mass FX pre/post results on Hepatic enzymes .Reference ranges for ALP, AST, and
ALT are 23‐144 U/L, 0‐46 U/L, and 0‐60 U/L, respectively. Ranges provided by Compunet Labs.
b
elevated
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Table 9
Hepatic Values for Placebo Group (U/L)a
Subject

ALP

AST

ALT

Pre

Post

Pre

Post

Pre

Post

PL1

47

44

20

20

24

24

PL2

65

66

30

24

31

31

PL3

134 119

28

27

34

26

PL4

102 109

32

34

27

30

Mean

87

27.5 26.25

29

27.75

S.D

38.80 35.46

5.25 5.90

4.39 3.30

84.5

a

Notes: Comparison for placebo pre/post results on hepatic enzymes. Reference ranges for ALP, AST, and
ALT are 23‐144 U/L, 0‐46 U/L, and 0‐60 U/L, respectively. Ranges provided by Compunet Labs.

Lipid Profiles
Lipid profiles were assessed by testing for LDL, HDL, VLDL, triglycerides, and
total cholesterol (See Tables 10 and 11). LDL, HDL, and total cholesterol showed a
model p value of <0.05. However, they were not considered significant models after
applying the Bonferroni correction. Mass FX supplementation did not affect any of lipid
markers (Group variable p>0.05).
It is worth mentioning that both LDL and HDL values fluctuated minimally in
some subjects. This could be due to diet and/or exercise as these values are often
influenced by them. Most subjects had less than optimal HDL levels during initial testing
which was also apparent during posttesting; thus, it was independent of supplementation.
There were no adverse changes in the Mass FX group on any of these lipid markers. One
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subject in the Placebo group (PL1) showed elevated LDL values during pre- and
posttesting, while another subject (PL2) had elevated LDL levels posttesting – a possible
cause could be diet.

Table 10
Lipid Profiles for Mass FX Group (mg/dl)a
Subject

LDL

HDL

VLDL

Triglycerides

Total C

Pre Post

Pre Post

Pre Post

Pre Post

Pre

MFX1

69

66

45

40

8

18

42

92

122

124

MFX2

73

69

57

46

16

8

82

41

146

123

MFX3

76

69

37

45

12

13

60

63

125

127

MFX4

85

79

58

53

7

8

36

41

150

140

Mean

75.5 70.75

49.25 46

10.75 11.75

55

59.25

135.75 128.5

S.D

6.80 5.67

10.07 5.35

4.11 4.78

20.68 24.17

a

14.29

Post

7.85

Note: Comparison for Mass FX pre/post results on lipid profiles. Reference ranges as provided
by Compunet: Triglycerides<150 mg/dl; total C <200 mg.dl; VLDL= 4‐28 mg/dl; LDL <100, HDL
>60 mg/dl.
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Table 11
Lipid Profiles for Placebo Group (mg/dl)
Subject

LDL

HDL

VLDL

Triglycerides

Total C

Pre Post

Pre Post

Pre Post

Pre Post

Pre Post

PL1

126b 128 b

44

46

25

18

126 90

195 193

PL2

91

110 b

27

29

19

19

93

96

137 158

PL3

94

75

42

36

16

19

82

94

152 130

PL4

55

65

61

69

9

9

45

47

125 143

Mean

91.5 94.5

43.5 45

17.25 16.25

86.5 81.75

152.25 155.75

S.D

29.03 29.51

13.91 17.45

6.65 4.85

33.39 23.30

30.65 26.73

a

Note: Comparison for Mass FX™ pre/post results on lipid profiles. Reference ranges as
provided by Compunet: Triglycerides<150 mg/dl; total C <200 mg.dl; VLDL= 4‐28 mg/dl; LDL
<100, HDL >60 mg/dl.
b
elevated

Complete Blood Count
Whole blood analysis was assessed by testing for white blood cell count (WBC),
white blood cell differential (neutrophils lymphocytes, monocytes, eosinophils, and
basophils), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute
eosinophils, absolute basophils. red blood cell count (RBC), hemoglobin, hematocrit,
platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC), red cell distribution width
(RDW). Absolute basophils were not analyzed due to all values equaling zero for both
groups during pre and post testing.
The only marker that exhibited significant change was the platelet count value
(Model significance p<0.05) and was considered significant at the family-wise level of α
= 0.05 using a Bonferroni correction at the pretreatment variable level. Despite the
significant change, the platelet count values remained within the reference ranges (See
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Tables 12 and 13). This change is not attributed to Mass FX supplementation (Group
variable p>0.05), but is due to changes from pretreatment values. The remainder of these
markers did not show any significant change (Model significance p>0.05).
All markers, except for one subject, MFX2, remained within the reference ranges
(See Table 18). For this subject, the monocytes and eosinophils were slightly elevated.
Monocytes were elevated pre- and posttesting; thus, this elevation is independent of
supplementation. Both changes in monocytes and eosinophils were minor. Possible
causes for this elevation might be due to infection, stress, and/or inflammation.

Table 12
Complete Blood Count Results for Mass FX Part 1 a
Subject

RBC

WBC

Platelets

m/mm3

k/mm3

K/mm3

Pre

Post

Pre

Post

Pre

Post

Pre

MFX1

5.29 5.32

4.8

5.6

223

229

15.7 15.8

46.7 47.3

MFX2

5.28 5.16

5.5

6.9

211

236

16.4 16

47.4 46.6

MFX3

5.01 5.11

4.5

5.7

211

211

14.7 15.3

43.2 45.5

MFX4

4.87 4.82

5.3

4.7

266

264

15.1 14.4

43.6 42.3

Mean

5.11 5.10

5.02 5.72

227.75 235

15.47 15.37

45.22 45.42

S.D

0.20 0.20

0.45 0.90

26.11 22.01

0.74 0.71

2.13 2.21

a

Hemoglobin
g/dl

Hematocrit
%

Post

Pre

Post

Notes: Comparison for Mass FX pre/post results on CBC parameter. Reference ranges as provided by
compunet: WBC 3.8‐10 K/mm3; RBC4.40‐5.8 M/mm3 ; Platelet count 130‐400 K/mm3 ; Hemoglobin: 13.8‐
17.2 g/dl; Hematocrit: 41‐50 %.
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Table 13
Complete Blood Count Results for Placebo Part 1 a
Subject

RBC
Pre

WBC
Post

Platelets

Hemoglobin

Hematocrit
Pre

Pre

Post

Pre

Post

Pre

Post

Post

PL1

5.17 7.7

7.3

5.16

271

260

15.9 15.8

46.4 46.6

PL2

5.32 5.38

6.7

5.6

180

188

15.8 16.1

46

47.5

PL3

4.97 4.65

4.8

5.8

291

261

14.7 13.8

43.3

41.1

PL4

4.83 4.69

4.4

4.3

246

247

15.2 14.9

43.9

43.2

Mean

5.07 5.60

5.8

5.2

247

239

15.4 15.15

44.9

44.6

S.D

0.21 1.43

1.41 0.66

0.55 1.03

1.52

2.97

48.31 34.59

a

Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as provided by
compunet: WBC 3.8‐10 K/mm3; RBC4.40‐5.8 M/mm3; Platelet count 130‐400 K/mm3 ; Hemoglobin: 13.8‐
17.2 g/dl; Hematocrit: 41‐50 %.

Tables 14 and 15 list the values of the changes in the red blood cell indices ,
RDW (Red cell distribution width), MCV (Mean corpuscular volume), MCH (Mean
corpuscular hemoglobin), and MCHC (Mean corpuscular hemoglobin concentration).
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Table 14
Complete Blood Count Results for Mass FX Part 2 a

Subject

RDW
Pre

MCV
Post

Pre

MCH
Post

Pre

MCHC
Post

Pre

Post

MFX1

12.3 12.4

88.4 88.8

29.7 29.8

33.5 33.5

MFX2

12.6 12.6

89.7 90.3

31.1 30.9

34.7 34.3

MFX3

13.5 13.5

86.1 89.1

29.3 29.9

34.1 33.6

MFX4

11.9 12.1

89.7 87.7

31

34.1 34.1

Mean

12.57 12.65

88.47 88.97

30.27 30.12

34.2 33.87

S.D

0.68 0.60

1.69 1.06

0.91 0.51

0.52 0.386

29.9

a

Notes: Comparison for Mass FX™ pre/post results on CBC parameters. Reference ranges as provided by
compunet: RDW: 9‐15 %; MCV: 80‐100 fL; MCH: 27‐33 pg; MCHC: 32‐36 g/dl.

Table 15
Complete Blood Count Results for Placebo Part 2 a

Subject

RDW
Pre

MCV
Post

Pre

MCH
Post

Pre

MCHC
Post

Pre

Post

PL1

13.3 13.1

89.8 90.4

30.8 30.6

34.3 33.9

PL2

12.6 13.7

86.5 88.3

29.6 29.8

34.3 33.7

PL3

13.6 12.1

87.1 92.2

29.6 31.8

34

PL4

12.2 12.6

91

31.5 29.9

34.6 33.8

Mean

12.95 12.87

88.6 89.82

30.37 30.52 34.3

33.95

S.D

0.63 0.68

2.14

0.93 0.92

0.31

88.4

1.85

a

0.24

34.4

Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as provided by
compunet: RDW: 9‐15 %; MCV: 80‐100 fL; MCH: 27‐33 pg/ml; MCHC: 32‐36 g/dl.
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Table 16
Complete Blood Count Results Mass FX Part 3 a
Subjects

ABS Neut.

ABS Lymph.

ABS Mono.

ABS Eosino.

ABS Baso.

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

MFX1

2.9

3

1.1

1.6

0.5

0.6

0.3

0.4

0

0

MFX2

2.9

4.2

1.9

1.8

0.5

0.6

0.2

0.2

0

0

MFX3

2.4

3

1.7

2.1

0.4

0.5

0.1

0.1

0

0

MFX4

3.2

2.6

1.7

1.7

0.3

0.3

0.1

0.1

0

0

Mean

2.85 3.2

1.6

1.8

0.42 0.5

0.17

0.2

0

0

S.D

0.33 0.69

0.34 0.21

0.09 0.14

0.09

0.14

0

0

Post

a

Notes: Comparison for Mass FX™ pre/post results on CBC parameters. Reference ranges as
provided by compunet: ABS Neut: 1.5‐7.8 K/mm3 ; ABS Lymph 0.9‐4.1 K/mm3; ABS Mono 0.2‐
1.1 K/mm3 , ABS Eosino 0‐0.6 K/mm3; ABS Baso. 0‐0.3 K/mm3

Table 17
Complete Blood Count Results for Placebo Part 3 a
Subjects

ABS Neut.

ABS Lymph.

ABS Mono.

ABS Eosino.

ABS Baso.

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

PL1

4.6

2.6

1.8

2.2

0.9

1

0.1

0.1

0

0

PL2

4.9

2.7

0.9

2.4

0.8

0.5

0.1

0.3

0

0

PL3

2.4

2

1.8

1.9

0.3

0.3

0.2

0.1

0

0

PL4

1.9

3.8

2.1

1.3

0.3

0.4

0.1

0.1

0

0

Mean

3.45 3.25

1.65 1.95

0.57 0.55

0.12 0.15

0

0

S.D

1.51 1.11

0.51 0.47

0.32 0.31

0.05 0.1

0

0

a

Post

Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as
provided by compunet: ABS Neut: 1.5‐7.8 K/mm3 ; ABS Lymph 0.9‐4.1 K/mm3; ABS Mono 0.2‐
1.1 K/mm3 ; ABS Eosino 0‐0.6 K/mm3; ABS Baso. 0‐0.3 K/mm3
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Table 18
Complete Blood Count Results for Mass FX Part 4 (%)a
Subject

Neutrophils

Lymphocytes

Monocytes

Eosinophils

Basophils

Pre

Pre

Pre

Pre

Pre

Post

Post

Post

Post

Post

MFX1

60.9

53.5

21.9 28

10.1 b 10.5 b

6.5

7.5 b

0.6

0.5

MFX2

52.4

61.4

35.2 26.5

9.2

8.9

2.8

2.8

0.4

0.4

MFX3

53.2

52

36.8 37

8.5

8.2

1.3

2.5

0.2

0.3

MFX4

59.6

54.4

31.9 36.8

6.4

6.6

1.6

1.6

0.5

0.6

Mean

56.52 55.32

31.45 32.07

8.55

8.55

3.05

3.6

0.42

0.45

S.D

4.34

6.68

1.57

1.61

2.38

2.64

0.17

0.12

4.16

5.60

a

Note: Comparison for placebo pre/post results on CBC parameters. Reference ranges as
provided by compunet: Neutrophils : 40‐75 % ; Lymphocytes 17‐47 %; Monocytes 0‐10 %,
Eosinophils 0‐7 %; Basophils 0‐2 %.
b
Minor elevation.

Table 19
Complete Blood Count Results for Placebo Part 4 (%)a
Subject

Neutrophils

Lymphocytes

Monocytes

Eosinophils

Basophils

Pre

Pre

Pre

Pre

Post

Pre

Post

Post

Post

Post

PL1

62.7 57.8

24.4 28.1

11.8 13

0.7

0.9

0.4

0.2

PL2

73.4 46.2

14

11.4

8.3

0.9

4.4

0.3

0.3

PL3

50.5

46.5

38.1 44.3

6.5

6.3

4.6

2.3

0.3

0.6

PL4

43.1

67.5

47

7.3

8

2.1

1.5

0.5

0.3

Mean

57.42 54.5

30.87 33.97

9.25

8.9

2.07

2.27

0.37 0.35

S.D

13.36 10.21

14.59 10.24

2.73

2.87

1.79

1.52

0.09 0.17

40.8

22.7

a

Note: Comparison for placebo pre/post results on CBC parameters. Reference ranges as
provided by Compunet: Neutrophils : 40‐75 % ; Lymphocytes: 17‐47 %; Monocytes: 0‐10 %;
Eosinophils: 0‐7 %; Basophils: 0‐2 %.
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Hypotheses Testing
In order to ascertain the effects of Mass FXTM on strength, testosterone, clinical
health markers, and body composition, the following null hypotheses were identified.
Based upon the results of this study, these hypotheses will now be addressed.
Ho1: Supplementation with Mass FX™ will not cause an improvement in body
composition. This hypothesis was rejected.
Ho2: Supplementation with Mass FX™ will not cause an increase in total testosterone.
This hypothesis was not rejected.
Ho3: Supplementation with Mass FX™ will not cause an increase in free testosterone.
This hypothesis was rejected.
Ho4: Supplementation with Mass FX™ will not cause an increase in muscular strength.
This hypothesis was rejected for the Bench Press only.
Ho5: Supplementation with Mass FX™ will not cause a change in clinical health markers.
This hypothesis was not rejected.
Summary
The data analyzed in this section were used to determine if there are any
significant differences in the results of both groups from pre trial testing. Despite
apparent improvements in the Mass FX group in the Primary outcomes, only one
parameter, the bench press was significant (Group variable p<0.05). In all secondary
outcomes, the results were not significantly affected by the Group variable (all p>0.05).
Therefore, it is suggested that supplementation with Mass FX does not affect the selected
clinical health markers.
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CHAPTER V
Discussion
This purpose of this chapter is four fold. First, the chapter will begin with
discussing the limitations faced in this study followed by a discussion of the major
findings. Furthermore, this chapter will address the recommendations for future studies.
Finally, this chapter will end with a conclusion addressing the efficacy of Mass FX.
Limitations
Unfortunately, this study had its limitations. A major limitation was the exclusion
of four subjects, which resulted in a larger variation between groups when comparing
their respective primary outcome, mean pretrial values. Before exclusion, the means of
the primary outcomes in between both groups had very little variation compared to after
exclusion (See Appendix H, Figures 11-17).
Not only are there group variations, but also there exists inter-subject variation in
primary outcomes. For example, initial values of testosterone concentrations between
subjects varied considerably. Some subjects were on the lower end of the reference range
(especially Mass FX group) whereas others were on the higher end of the reference
ranges (Placebo). This could be attributed to the different ethnicities represented in this
study. Various studies have shown apparent differences in androgen levels between
different racial and ethnic groups (Wu et al., 1995; Ellis et al., 1992; Ross et al., 1986;
Winters et al., 2001). Hence, this should be considered when analyzing the data. Not only
that, but there are other factors that might influence baseline testosterone concentrations.
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These factors include genetics, hormonal regulation, health status, activity levels, diet,
external factors, and emotions (Warren & Constantini, 2000, p.3).
Another inter-subject variation was the initial strength values. These variations
could be attributed to previous weight training experience mode, bodyweight, aggression,
and motivation of the subjects. Therefore, keeping all of these aforementioned factors in
mind, this study should strictly be considered a pilot study until future studies are
performed with better recruiting strategies and larger samples sizes.
There were various reasons that led to the exclusion of the subjects. In detail, two
subjects from each group were excluded from the trial. The first subject in the Placebo
group abruptly stopped working out and taking the supplementation and decided not to
continue the trial. While, the second subject in the same group suffered from
streptococcal pharyngitis and was taking medications including Ambien ™, amoxcillian,
and a dietary supplement, ZMA®.
In the Mass FX group, one subject was excluded due to diagnosis of a
hematological anomaly. Initial blood testing showed signs of microcyctic anemia.
Analysis revealed moderate levels of unequal red blood cell size (anisocytosis). In
addition, a marked presence of very small red blood cells (microcytosis) was observed
and giant platelets were noted. There was also a slight variation in the hemoglobin
content in his red blood cells (polychromasia). There was a presence of moderate
amounts of elliptocytes (ovalocytes), oval shaped red blood cells, in his blood samples.
Furthermore, the blood analysis revealed low hemoglobin (10.6 g/dl), hematocrit (34.3
%), MCV (58.3 fL), MCH (18 pg), and MCHC (30.8 g/dl). Finally, high values for both
RDW (19.6 %) and RBC count (5.87 m/mm3) were noted.
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The second Mass FX subject was excluded for not following recommended
dietary guidelines, especially fat intake. His fat calories were around 5-10 % of total
calories. This was about 15-20 % difference between the recommended guidelines (25 %
fat calories from total calories). For the sake of the study, it was necessary to have a
higher fat intake as it is crucial for testosterone production. Dorgan et al. (2000) have
shown that diets with low fat intakes are associated with lower androgen production in
comparison to higher fat diets. Also, Hamalainen et al. (1983) have shown that dietary fat
intake less than 25% of total calories reduces androgen concentrations in healthy men.
Therefore, the 25% fat calories utilization in this study was based on Hamalainen et al.’s
findings. Thus, any subject whose fat intake was lower than recommended was excluded
from this study. Not only that, but fat may play a role in exercise induced testosterone
increases that may contribute to better hypertrophy adaptations (Sallinen, 2007). Hence,
low fat intakes may negate this benefit.
Discussion
Surprisingly, the Placebo group had major reductions in both total and free
testosterone. This observation could be explained by the intensive training program that
the subjects underwent. Studies involving intensive training have shown significant
reductions in testosterone concentrations (Flynn et al., 1994). In addition, these decreases
may suggest an incomplete recovery from intense training (Vervoorn et al., 1991).
Interestingly enough, the lower testosterone concentration didn’t reduce the muscular
strength of the subjects in comparison to pretrial strength measurements. These findings
were similar to the study by Vervoorn et al. (1991) which showed that a lower
testosterone/cortisol ratio did not negatively affect exercise performance.
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Despite compliance to diet and training, the Placebo group showed minor to no
improvements in the 1 repetition max strength tests. Various factors affect muscle
strength. One such factor to consider is limb length because individuals with longer limbs
are at a biomechanical disadvantage. Another factor to keep in mind is possible
overtraining/overreaching due to the intensive training program, which may result in
muscle and central nervous system fatigue. The training protocol in this trial was
considered high volume in nature. Interestingly, Moore & Fry (2007) have shown that
high volume training can result in poor performance with significant decreases in
testosterone concentrations. These results closely resemble the findings in this trial.
Therefore, it is suggested that Mass FX might help in offsetting some overreaching
symptoms since the Mass FX group was void of any overreaching/overtraining
symptoms.
Only one subject in the Placebo (PL2) had his total testosterone increase from
pretesting. The increase was not significant, but a change of 1.2 % was noted (See Table
7). This could be a result of the body trying to compensate for the decrease in free
testosterone via feedback mechanisms (See Figure 8).
As for testosterone observations for the Mass FX group, all subjects reported
impressive improvements in free testosterone. A study conducted by Ahtiainen et al.
(2003) suggested that increases in basal testosterone levels might be a significant factor
in considering strength improvements. Interestingly enough, the Mass FX group had
obvious increases in basal free testosterone levels in comparison to pretrial basal values
and greater improvements in strength compared to Placebo. Thus, it is suggested that
there might be a correlation between muscular strength and free testosterone levels in the
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Mass FX group. Therefore, it may be valid to assume that the increases in strength in the
Mass FX group might be attributed in part to the increases in free testosterone.
The mean percent difference increase in free testosterone from pretesting was
75.84 %. In addition, excluding the two subjects (MFX2 and MFX4), all exhibited
increases in total testosterone concentrations – the subjects had minor drops (2.9 and 7.07
%, respectively). Generally, total testosterone concentrations change in relation to
changes in free testosterone concentrations via SHBG concentrations (Kelly &
Vankrieken, 1997; Nieschlang et al., 2004, p.643). This is due to the fact that free and
protein bound testosterone in blood are in state of equilibrium (Nieschlang et al., 2004,
p.643). Therefore, any changes in the concentration of free testosterone levels would
result in changes in total testosterone levels. For example, increased SHBG
concentrations reduce free testosterone and increases total testosterone (Anderson, 1974);
therefore, it is suggested that an inverse relationship might exit between these three
clinical markers. Thus, a rise in free testosterone via SHBG might result in a decrease in
total testosterone and vice versa. It would have been interesting to determine whether the
changes in total and free testosterone were a result of SHBG concentration differences.
This could have been achieved by analyzing SHBG concentrations via a blood analysis. It
is suggested that the apparent increases in free testosterone due to Mass FX (probably via
SHBG inhibition) caused this decrease in total testosterone concentrations of subjects
MFX2 and MFX4. These minor reductions could be attributed to a homeostatic
mechanism in which the body is trying to regulate the balance of bioavailable and bound
testosterone. Due to these possible changes, it would be recommended to use Mass FX in
microcycles of six weeks as exemplified in this study. This is recommended to prevent
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any possible reductions in total testosterone via feedback inhibitions in response to
elevated serum free testosterone levels.
In addition to SHBG regulation, testosterone concentrations are regulated by
negative feedback loops to the hypothalamus and anterior pituitary (See Figure 8). An
increase in testosterone concentrations signals the hypothalamus to decrease secretion of
GnRH, which in turn decreases gonadtropin production. Not only that, but increased
testosterone levels also contributes to less LH secretion in response to GnRH from the
anterior pituitary (Widmaier et al., 2004, p.654-655). This might explain the total
testosterone increase in the placebo subject (PL2).

Figure 10: Regulation of testosterone via feedback mechanisms (Widmaier et al., 2004, p.654)
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As for side effects, no adverse events were reported by any of the subjects for
both groups. However, the Mass FX group reported increases in libido. This effect was
reported during the 2nd and 3rd week of the trial.
To determine the power of the samples used in this study, a posthoc Power
Analysis (See Table 22) was performed to test an effect for Mass FX (if it existed). It was
determined that the data required an 88.6% power level to detect the effect of Mass FX
for the bench press outcome which was achieved. This indicates that the bench press
significance was valid. There was nearly 80% power for the Free Testosterone outcome,
indicating that Mass FX might have had a significant effect if the sample size was larger.
The other tests had very low power to detect the effect of Mass FX, if it exists. For those
variable, it is not certain if the lack of significant change was due to the small sample size
or the lack of a real effect.
As for the secondary outcomes, the clinical health marker variables, the power
was very low for all. The conclusion that Mass FX did not appear to have an effect on
these markers (It was not possible to reject the null hypothesis that it had no effect), is
more likely due to the fact that there was insufficient power (small sample size) to see
that effect, if it existed.
Recommendations
A suggestion that would have made this study better, would have been to use
larger sample sizes in both groups. However, due to limitations during recruiting and
exclusion of four subjects, the resulting sample size was eight subjects total with four
subjects in each group. In turn, this trial may be considered a pilot study.
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In addition, future studies should measure muscle circumferences from various
parts of the body such as arm, calves, thighs, and chest/back to determine whether Mass
FX supplementation induces larger circumference changes than Placebo. Not only that,
but measuring muscle cross sectional areas of specific muscle groups such as thighs is
another parameter to address in future studies. This could illustrate whether Mass FX
supplementation induces larger muscle hypertrophy responses than Placebo. These
measures can be obtained by using computed tomography (CT), magnetic resonance
imaging (MRI), and/or dual-energy X-ray absorptiometry (DEXA).
Another recommendation for future studies would be measuring other clinical
parameters such as SHBG. This would help in drawing conclusions as to whether the
increases in free testosterone were a result of a decrease in SHBG production (as
mentioned earlier). Measurement of other clinical markers such as testosterone
metabolites, namely dihydrotestosterone (DHT) and estrogen (E), would be considered
valuable. Quantifying E would help in investigating whether Mass FX modulates
aromatase, an enzyme involved in the metabolism of testosterone into estrogen. In turn,
this would explain if the total testosterone increases in the Mass FX group were due to
feedback mechanisms via aromatase/estrogen inhibition as observed with other studies
involving aromatase inhibition (Willoughby et al., 2007; Rohle et al., 2007).
Analyzing muscle samples for myogenic regulatory factors (MRFs) would have
been an interesting addition to the set of data compiled in this study. MRFs such as
MRF4, MyoD and Myf5, have been shown to be involved in muscle fiber adaptations
during hypertrophy (Hespel et al., 2001). Thus, by analyzing the expression of these
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regulatory factors, conclusions can be made to see if Mass FX has an effect on MRFs and
correlate the findings to hypertrophy measures such as lean mass gain.

Conclusion
In conclusion, this study suggests that Mass FXTM has ergogenic benefits when
taken during a controlled diet and exercise program. The data also suggest that Mass
FXTM does not affect selected clinical health markers such as CBC with differentials,
hepatic, renal, and lipid profiles and thus, appears safe when taken within recommended
doses. It is recommended that future studies should utilize larger sample size to obtain
statistical significance of findings.
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APPENDIX A
AHA/ACSM HEALTH/FITNESS FACILITY PREPARTICIPATION SCREENING
QUESTIONNAIRE.

68

69

APPENDIX B
INFORMED CONSENT
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Department of Biological Sciences
Exercise Biology Program
3640 Colonel Glenn Hwy
Dayton, OH 45435-0001
(937) 775-2655
FAX (937) 775-3320

INFORMED CONSENT

TITLE: Effects of a combination of plant extracts, chlorogenin and (-)-3,4
divanillyltetrahydrofuran, on exercise performance, body composition, and blood
chemistries in adult males.

Please read this entire informed consent. It will explain procedures for which your
consent and participation are requested.

AGREEMENT TO PARTICIPATE:

I have been asked to participate in this

research study because I am between 21-30 years of age, have had at least six months of
weight lifting experience, and am healthy. This signed consent is to certify my
willingness to participate in this research study.

PURPOSE OF STUDY:

This study is designed to determine the effects of the

dietary supplement, Mass FX™, on exercise performance, body composition, and blood
chemistries in experienced resistance-trained (weight trained) males.. It is also expected
that testosterone (free testosterone) levels will be significantly elevated, while health
markers (liver enzymes (alanine transaminase, aspartate transaminase), RBC and WBC
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counts, lipid profiles (total cholesterol/ LDL/HDL), and kidney function (creatinine/blood
urea nitrogen) remain significantly unchanged.

PROCEDURES:

All testing procedures will be performed in the Exercise Biology

Laboratory at Wright State University according to the following schedule. All training
will take place at the WSU Fitness Center.
Week 0:
•

Visit 1: Complete a Health history and demographic questionnaire, as well as
answer questions about my health and exercise history. Read and sign a consent
form, have my resting blood pressure, resting heart rate, height, and weight
measured, complete a Pre-trial body composition analysis, and have a teaspoon
of blood drawn from my forearm. This visit will last about 1 hour.

Eligibility determination
To insure that I am “apparently healthy” as recommended by the American College
of Sports Medicine Guidelines (ACSM, 2006) for participating in sports and physical
activity, I will fill in an AHA/ACSM Health/Fitness Facility Preparticipation Screening
Questionnaire prior to engaging in this study.
To be eligible for this study, I can have no more than one coronary artery disease risk
factor and no signs/symptoms of metabolic, endocrine, or cardiopulmonary disease. In
addition, I cannot be taking any taking any medication [prescription or over-the-counter]
or other nutritional supplements before and during the study period.

Informed consent
After determining eligibility status, the primary investigator (Mr. Patrick Dib) will
fully explain the procedures and methodology involved in the study to me. Mr. Dib will
also answer all questions that I may have. I am aware that my participation is voluntary
and that I reserve the right to withdraw at any time without penalty.
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Demographics
After signing the informed consent, the primary investigator will begin to obtain
measurements for the pre-study parameters from me. First, the primary investigator will
gather my demographic information, which includes my initials, date of birth, height,
blood pressure, heart rate, body weight, and body fat.
Other Measurements [These measurements will take approximately 1 hour]
Resting blood pressure will be measured by using a Marshall medical measuring kit.
The systolic and diastolic portions of the blood pressure will be taken. In a seated
position (legs uncrossed), measurements will be taken with my left forearm positioned on
a cushion on a table at heart level. Blood pressure measurements will be recorded twice
with 5 minutes rest in between each reading. The average of both readings will be
recorded. However, if there is more than a five mmHg difference between the 2 readings,
a third reading will be performed after a 5 minute rest. The average of all 3 readings
would be recorded in this case.
Resting heart rate will be measured using a polar heart rate monitor while I am
sitting in a chair (legs uncrossed). The investigator will attach the transmitter to the
elastic strap, adjust and secure the strap to my chest just below the chest muscles. Finally,
the investigator will lift the transmitter up and moisten the grooved electrode areas with
water on the back and make sure that the electrode is firmly against my skin and that the
Polar logo is in a central, upright position (Polar, 2002).
Height will be measured without shoes and socks to the nearest 0.1 inch using a
stadiometer [an instrument for measuring height] (SECA, 2006, Germany). Prior to
taking the measurement, I will be asked to stand with both feet and heels together and
arms at my side. I will be directed to keep my head level with my eyes fixed straight
ahead.
Body fat and weight will be measured via a recently calibrated BOD/POD
(1997,Concord, CA). I will wear spandex or compression shorts and remove all jewelry
and accessories. I will be given a Speedo© head cap to cover my hair.
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I will step into the Bod Pod device and sit down with my hands folded in my lap. I
will breathe normally and sit quietly until the assessment is complete. The entire test will
take approximately five minutes.
•

Visit 2: Muscle strength testing This visit will last about 1 hour.
I will be asked to perform a three muscular strength tests. These tests will be

done in a 1 Repetition Maximum (1-RM) manner. 1-RM tests are performed in a gradual
fashion with added weight on each trial until I cannot perform a complete lift in good
form. I will start my lifts with a low weight. If I perform the lift properly, five pounds
will be added to the next attempted lift. This will continue until I can no longer lift the
specified amount of weight. The last amount of weight lift complete and in good form
will be recorded as my 1 RM. During these tests, a spotter will be available to minimize
the risk of injury and to ensure the proper execution of the exercises. The three tests I
will perform are the bench press, leg press, and deadlift.
Bench Press
The procedures for the bench press are as follows:
1. With the barbell on the rack, I will lie on the bench so that the bar is above my
head.
2. I will bring my hands up and hold the bar just wider than shoulder width apart.
3. I will lift the barbell off the rack and extend my arms until they're straight.
4. Then I will slowly lower the weight until the bar almost touches my chest.
5. I will slowly lift the weight back up.
6. Spotters will be on either side of the bar to assist the lift.

Leg Press
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The procedures for the leg lift are as follows:
1. I will sit in the leg press machine with my body at a 45o angle and my feet about
shoulder width apart
2. The bars will be released.
3. I will push the plate away until my legs are straight.
4. I will slowly return to starting position.
5. Spotters will be at my side to assist the lift.

Deadlift
The procedures for the deadlift are as follows:
1. With the barbell on the floor, I will squat down and hold the bar at about shoulder
width. My back will be straight.
2. With my back straight, I will slowly lift the weight until I am standing straight.
3. This position will be held for a second.
4. The weight will be slowly lowered back to the floor.
•

Visit 3: This visit will last about 30 minutes.
o Review resistance training protocol
o Review supplementation protocol
o Review of dietary recommendations

Training Protocol
I will be asked to perform a specific exercise program 3 times a week with
recommendations on what I should eat while training (see attached). I will not perform
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any additional exercise outside the study. I will be monitored on every workout session
by Mr. Dib or a trained senior Exercise Biology major to ensure all safety precautions are
in followed and observed for any health changes. Mr. Dib will call me by phone, daily,
to ensure that I am not having any health problems.

Supplementation Protocol and Dietary Recommendations
I will be asked to take 1 supplement capsule 4x/day. One capsule will be taken
with breakfast, another capsule with lunch, another capsule with a midday snack, and the
final capsule will be taken with dinner. Each capsule will be taken with a full glass of
water.
I will be asked to record the times in which I take the supplement on a
supplementation log (attached).
During the six weeks of training, I will be asked to try and eat a healthy and
balanced diet. I will be given a recommended diet. (attached).
I will be asked to record my diet for the duration of the study on a diet log.
Weeks 1-6: Training at the WSU Fitness Center
Week 7:
•

Visit 1: Post trial body composition testing; post trial blood draw

•

Visit 2: Post trial muscle strength testing\

These tests are identical to the tests performed on visits 1 and 2 in week 0.
BENEFITS AND RISKS: I understand that there is risk of muscle soreness as a result of
exercise testing and the workout program. In addition, there is risk of injury when
performing exercise; however, I will be supervised by the primary investigator and his
assistants to minimize this risk. I also understand that supplementing my diet with Mass
FX® may cause some acne, oily skin, increased body hair, and/or minor hair shedding
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because of elevated testosterone levels. In addition, as with any nutritional supplement,
Mass FX™ may carry rare incidences of unknown risks. Also, at the site where a small
sample of blood will be taken (venipuncture), a small bruise and soreness may develop.
The benefits to my participation in this study include the knowledge gained from data
collected from my exercise performance, body composition, and blood chemistries. I may
also benefit from an organized and supervised workout program. Finally, I will be given
all my individual results of the testing performed in this study.
ADDITIONAL COSTS: There is no cost to me to participate in the study.
ALTERNATIVES: There are no alternatives to this procedure
REMUNERATION: There is no compensation for this study.
CONFIDENTIALITY: . Participation in research may involve a loss of privacy, but
information about me will be handled as confidentially as possible. All personal
information will be kept in a file cabinet in the exercise biology office. Finally, I am
aware that only the primary investigator and the thesis chair will have access to my
information. The access to my information is strictly for academic purposes. My name
will not be included if these data are presented in written or oral form. Only group and
nonidentifiable individual results [e.g., Subject 1, Subject 2, etc.] will be reported.
Because of the nature of the pre-and posttests, you will know your scores on the body
composition, resting blood pressure, resting heart rate, and body composition.

Keeping Study Records: Mr. Dib will retain my research records, including information
from my medical history form, indefinitely for research purposes. However, my personal
health information cannot be used for additional research without additional approval
from me.
COMPENSATION/LIABILITY STATEMENT: You will receive medical help if
injured in this research study. You and/or your health plan will be charged for this
treatment. The study will not pay for medical treatment.
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EXPLANATION RECEIVED: I hereby acknowledge that this study has been
explained to me and that the principal investigator (Mr. Patrick Dib) has discussed the
possible risks and side effects associated with this study. I also certify that I was given
the opportunity to have all my questions answered by the primary investigator regarding
this study.
QUESTIONS / CONTACT PERSONS: For more information about this study, or in
the unlikely event of injury, I may contact Mr. Patrick Dib, primary investigator at 310570-6359 (cell) or Roberta Pohlman, Ph.D., Director, Exercise Biology Program at 937775-2858 [Department of Biological Sciences, 265 Biology Hall, 775-2655] . I may also
contact the WSU Institutional Review Board at 201J University Hall, Wright State
University, Dayton, Ohio 45435, (937) 775-4462.
Obtaining Results: If you would like to receive the values for your blood
chemistry and the study results when evaluated we will provide you with a self-addressed
postcard requesting this information at the end of the study
VOLUNTARY CONSENT: PARTICIPATION IN RESEARCH IS VOLUNTARY. I
hereby reserve the right to refuse to participate in this study or to withdraw at any given
time. My decision to participate or not to participate will not negatively affect my care at
this institution or cause a loss of benefits to which I might otherwise be entitled. I may
also withdraw my conset for this study to use my personal health information by contacting
Patrick Dib to inform him of my decision. If I withdraw my consent, the information
already collected may continue to be used, to maintain the integrity of the study
My signature below means that I have freely and willingly and without any external
influence, agreed to participate in this aforementioned research study.

Signature/Date Lines:
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______________________________________________________________________
Printed Name of Participant

______________________________________________________________________
Signature of Participant

Date

Signature of Witness

Date

________________________________________________________________________
Signature of Primary Investigator

Date

Mr. Patrick Dib
235 Biological Sciences
College of Science and Math
775-2858
dib.2@wright.edu
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APPENDIX C
DIETARY RECOMMENDATIONS
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Dietary intake is customized to each subject as follows:
• Total calories:
Total caloric intake: (Bodyweight * 14) + 500
•

Protein:

1.2g/lb of bodyweight = Protein intake in g/day
1.2g/lb of bodyweight * 4 = Total calories from protein/day
•

Fats:

Total caloric intake * 0.2 = Total fat calories/day
Total fat calories/9 = amount of fat in g/day
•

Carbohydrates:

Total calories from carbs: Total caloric intake- (Total protein calories/day + Total
fat calories/day).
Total calories from carbs / 4 = Total grams of carbs/day
After determining the amount of each macronutrient subjects were recommended to use
the following food choices to reach their recommended caloric intake.
Protein: Lean red meats, poultry, pure whey protein powder, egg whites, fish
Carbohydrates: whole wheat bread and pasta, brown rice, oats, yams, sweet
potatoes, veggies
Fats: olive oil, nuts, egg yolk, natural peanut butter, fish fats,
Supplements: 4 caps/day split as follows:
1 capsule 15-20 minutes before breakfast, lunch and dinner
1 capsule 30-45 minutes pre-workout.
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APPENDIX D
WORKOUT PROGRAM
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Upper: Monday/Thursday
Flat Bench: 3 sets 8-10 reps
Incline Bench: 3 sets 8-10 reps
Military Press: 3 sets 8-10 reps
Upright rows: 2 sets 8-10 reps
DB rows: 2 sets 8-10 reps
Barbell Rows: 3 sets 8-10 reps
pulldowns: 3 sets 8-10 reps
Cleans: 1 set 15-20 (Light Weight, feel the burn)
Barbell Curls: 2 sets 8-10 reps
French Curls: 2 sets 8-10 reps

Lower: Tuesday/Friday
Deadlift: 3 sets 8-10 reps
Leg Press: 3 sets 8-10 reps
Superset*: 3 sets 8-10 reps
-Leg Extension
-Leg curls
Back squats: 1 sets 15-20 (light weight, slow tempo)
Leg Press: 2 sets 15-20 (light weight, slow tempo)

Seated Calf raises: 3 sets 8-10 (Slow rep tempo)
Standing or donkey Calf raises: 3 sets 8-10 (Slow rep tempo)

*: superset denotes that the 2 exercises should be done back to back . Subject should
rest after both exercises are done. Then repeat for given amount of sets.
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Subject Name:

ID#

Date of Birth:

Height (inches):

Weight (pounds):
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APPENDIX F
SELECTED CLINICAL HEALTH MARKERS
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Complete blood count: White blood cell count (WBC), White blood cell differential:
(neutrophils lymphocytes, monocytes, eosinophils, basophils,), Absolute neutrophils,
Absolute lymphocytes, Absolute monocytes, Absolute eosinophils, Absolute basophils.
Red blood cell count (RBC), Hemoglobin, Hematocrit, platelet count, Mean corpuscular
volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin
concentration (MCHC), Red cell distribution width (RDW). Lipid Profile: Low Density
Lipoprotein (LDL), High Density Lipoprotein (HDL) , Very Low Density Lipoprotein
(VLDL), Triglycerides (TG), Total cholesterol (TC). Hepatic: Alkaline phosphatase
(ALP), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Renal:
Creatinine, Blood Urea nitrogen (BUN).
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APPENDIX G
STATISTICAL ANALYSIS
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Table 20
Primary Outcomes statistical analysis
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Table 21*
Secondary Outcomes statistical analysis

a

Notes: ALT,AST,LDL,HDL,Total Cholesterol, and creatinine were not
considered significant models after applying the Bonferroni correction.
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Table 22: Posthoc Power analysis
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Figure 11:Comparison of pretrial free testosterone variation before and after exclusion of subjects.
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Figure 12: Comparison of pretrial total testosterone variation before and after exclusion of subjects.
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Figure 13:Comparison of pretrial fat free mass variation before and after exclusion of subjects.
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Figure 14:Comparison of pretrial fat mass variation before and after exclusion of subjects.
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Figure 15: Comparison of pretrial bench press variation before and after exclusion of subjects.
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Figure 16: Comparison of pretrial leg press variation before and after exclusion of subjects
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Figure 17: Comparison of pretrial deadlift variation before and after exclusion of subjects
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